

MATION CENTRE ON HPV AND **Human Papillomavirus** and **Related Diseases Report**



JIVARC IN

Version posted at www.hpvcentre.net on 10 March 2023

Copyright and Permissions

©ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre) 2023

All rights reserved. HPV Information Centre publications can be obtained from the HPV Information Centre Secretariat, Institut Català d'Oncologia, Avda. Gran Via de l'Hospitalet, 199-203 08908 L'Hospitalet del Llobregat (Barcelona) Spain. E-mail: hpvcentre@iconcologia.net. Requests for permission to reproduce or translate HPV Information Centre publications - whether for sale or for noncommercial distribution- should be addressed to the HPV Information Centre Secretariat, at the above address. Any digital or printed publication of the information provided in the web site should be accompanied by an acknowledgment of HPV Information Centre as the source.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part the HPV Information Centre concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers products does not imply that they are endorsed or recommended the HPV Information Centre in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the HPV Information Centre to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the HPV Information Centre be liable for damages arising from its use.

Recommended citation:

Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Czechia. Summary Report 10 March 2023. [Date Accessed]



Executive summary

Human papillomavirus (HPV) infection is now a well-established cause of cervical cancer and there is growing evidence of HPV being a relevant factor in other anogenital cancers (anus, vulva, vagina and penis) and head and neck cancers. HPV types 16 and 18 are responsible for about 70% of all cervical cancer cases worldwide. HPV vaccines that prevent against HPV 16 and 18 infection are now available and have the potential to reduce the incidence of cervical and other anogenital cancers.

This report provides key information for Czechia on cervical cancer, other anogenital cancers and head and neck cancers, HPV-related statistics, factors contributing to cervical cancer, cervical cancer screening practices, and HPV vaccine introduction. The report is intended to strengthen the guidance for health policy implementation of primary and secondary cervical cancer prevention strategies in the country.

Table 1: Key Statistics

Women at risk for cervical cancer (Female population aged >=15 yrs)		4.51 million
Burden of cervical cancer and other HPV-related cancers		
Annual number of cervical cancer cases		769
Annual number of cervical cancer deaths		398
Crude incidence rates per 100,000 population:	Male	Female
Cervical cancer	-	14.1
Anal cancer	1.44	2.02
Vulva cancer	-	5.08
Vaginal cancer	-	0.90
Penile cancer	2.37	-
Oropharyngeal cancer	7.17	2.69
Oral cavity cancer	10.8	5.87
Laryngeal cancer	8.12	1.32
Burden of cervical HPV infection		
Prevalence (%) of HPV 16 and/or HPV 18 among women with:		
	Normal cytology	6.6
Low-grade cervical le	sions (LSIL/CIN-1)	33.7
High-grade cervical lesions (HSII	/CIN-2/CIN-3/CIS)	63.3
	Cervical cancer	79.3
Other factors contributing to cervical cancer		
Smoking prevalence (%) [95% UI], women		27 [20.5-33]
Total fertility rate (live births per women)		1.6
Oral contraceptive use (%)		54.4
HIV prevalence (%) [95% UI], women (15-49 years)	<0.1 [<0.1 -<0.1]	
Sexual behaviour		
Percentage of 15-year-old who have had sexual intercourse (men/women)		23.0/24.0
Range of median age at first sexual intercourse (men/women)		17.0/17.0-17.5
Cervical screening practices and recommendations		
Existence of official national recommendations		Yes
Starting year of current recommendations		2014
Active invitation to screening		Yes
Screening ages (years), primary screening test used, and screening interval or fr	equency of screen-	25-60 (cytology, 1
ings		year)
HPV vaccine in females		.
HPV vaccination programme		Introduced
Year of introduction		2012
Year of estimation of HPV vaccination coverage		2021
HPV coverage – first dose (%)		-
HPV coverage – last dose (%)		-

* Please see the specific sections for more information.

Population

Contents

Ex	xecutive summary ii			iii
1	Intr	roduct	ion	2
2	Den	nograp	phic and socioeconomic factors	4
3	Bur	den of	f HPV related cancers	5
	3.1	HPV 1	related cancers incidence	5
	3.2	HPV 1	related cancers mortality	7
	3.3	Cervie		9
		3.3.1		9
		3.3.2	Cervical cancer incidence by histology in Czechia	
		3.3.3	Cervical cancer mortality in Czechia	
		3.3.4		
	3.4		enital cancers other than the cervix	
		3.4.1	Anal cancer	
			3.4.1.1 Anal cancer incidence in Czechia	
			3.4.1.2 Anal cancer mortality in Czechia	
			3.4.1.3 Anal cancer incidence and mortality comparison in Czechia	
		3.4.2	Vulva cancer	
			3.4.2.1 Vulva cancer incidence in Czechia	
			3.4.2.2 Vulva cancer mortality in Czechia	
		0.4.0	3.4.2.3 Vulva cancer incidence and mortality comparison in Czechia	
		3.4.3	Vaginal cancer	
			3.4.3.2 Vaginal cancer mortality in Czechia	
			3.4.3.3 Vaginal cancer incidence and mortality comparison in Czechia	
		3.4.4	Penile cancer	
		5.4.4	3.4.4.1 Penile cancer incidence in Czechia	
			3.4.4.2 Penile cancer mortality in Czechia	
			3.4.4.3 Penile cancer incidence and mortality comparison in Czechia	
	3.5	Head	and neck cancers	
	0.0	3.5.1	Oropharyngeal cancer	
		0.0.1		38
			3.5.1.2 Oropharyngeal cancer mortality in Czechia	
			3.5.1.3 Oropharyngeal cancer incidence and mortality comparison in Czechia	
		3.5.2	Oral cavity cancer	
			3.5.2.1 Oral cavity cancer incidence in Czechia	
			3.5.2.2 Oral cavity cancer incidence and mortality comparison in Czechia	
			3.5.2.3 Oral cavity cancer incidence and mortality comparison in Czechia	
		3.5.3	Laryngeal cancer	48
			3.5.3.1 Laryngeal cancer incidence in Czechia	48
			3.5.3.2 Laryngeal cancer incidence and mortality comparison in Czechia	50
			3.5.3.3 Laryngeal cancer incidence and mortality comparison in Czechia	52
4	нр	V relat	ted statistics	53
•			burden in women with normal cervical cytology, cervical precancerous lesions or	
				53
				54
		4.1.2	HPV type distribution among women with normal cervical cytology, precancerous	
				55
		4.1.3	HPV type distribution among HIV+ women with normal cervical cytology	65

	4.2 4.3 4.4	4.1.4 Terminology66HPV burden in anogenital cancers other than cervix674.2.1 Anal cancer and precancerous anal lesions684.2.2 Vulvar cancer and precancerous vulvar lesions704.2.3 Vaginal cancer and precancerous vaginal lesions734.2.4 Penile cancer and precancerous penile lesions75HPV burden in men77HPV burden in the head and neck784.4.1 Burden of oral HPV infection in healthy population784.4.2 HPV burden in head and neck cancers79
5	Fac	ors contributing to cervical cancer 81
6	Sex	al and reproductive health behaviour indicators 82
7	7.1	preventive strategies85Cervical cancer screening practices85HPV vaccination87
8	Pro	ective factors for cervical cancer 89
9	Ann 9.1	ex90Incidence909.1.1Cervical cancer incidence in Czechia across Eastern Europe909.1.2Anal cancer incidence in Czechia across Eastern Europe939.1.3Vulva cancer incidence in Czechia across Eastern Europe989.1.4Vaginal cancer incidence in Czechia across Eastern Europe1019.1.5Penile cancer incidence in Czechia across Eastern Europe1049.1.6Oropharyngeal cancer incidence in Czechia across Eastern Europe1079.1.7Oral cavity cancer incidence in Czechia across Eastern Europe1129.1.8Laryngeal cancer incidence in Czechia across Eastern Europe1129.1.4Laryngeal cancer incidence in Czechia across Eastern Europe1129.1.8Laryngeal cancer incidence in Czechia across Eastern Europe1229.2.1Cervical cancer mortality in Czechia across Eastern Europe1229.2.2Anal cancer mortality in Czechia across Eastern Europe1309.2.4Vaginal cancer mortality in Czechia across Eastern Europe1339.2.5Penile cancer mortality in Czechia across Eastern Europe1339.2.6Oropharyngeal cancer mortality in Czechia across Eastern Europe1369.2.6Oropharyngeal cancer mortality in Czechia across Eastern Europe1399.2.7Oral cavity cancer mortality in Czechia across Eastern Europe1399.2.7Oral cavity cancer mortality in Czechia across Eastern Europe1449.2.8Laryngeal cancer mortality in Czechia across Eastern Europe149

10 Glossary

154

List of Figures

1	Czechia and Eastern Europe	2
2	Population pyramid of Czechia for 2022	4
3	Population trends in four selected age groups in Czechia	4
4	Comparison of HPV related cancers incidence to other cancers in men and women of all ages in Czechia (esti-	
	mates for 2020)	5
5	Comparison of HPV related cancers incidence to other cancers among men and women 15-44 years of age in	
	Czechia (estimates for 2020)	6
6	Comparison of HPV related cancers mortality to other cancers in men and women of all ages in Czechia (esti-	0
0		-
_	mates for 2020)	7
7	Comparison of HPV related cancers mortality to other cancers among men and women 15-44 years of age in	
	Czechia (estimates for 2020)	8
8	Age-specific incidence rates of cervical cancer in Czechia (estimates for 2020)	11
9	Annual number of new cases of cervical cancer in Czechia (estimates for 2020)	
10	Time trends in cervical cancer incidence in Czechia (cancer registry data)	13
11	Age-specific mortality rates of cervical cancer in Czechia (estimates for 2020)	15
12	Annual number of deaths of cervical cancer in Czechia (estimates for 2020)	15
13	Comparison of age-specific cervical cancer incidence and mortality rates in Czechia (estimates for 2020)	16
	Comparison of annual premature deaths and disability from cervical cancer in Czechia to other cancers among	10
14		10
	women (estimates for 2019)	17
15	Age-specific incidence rates of anal cancer in Czechia (estimates for 2020)	19
16	Annual number of new cases of anal cancer in Czechia (estimates for 2020)	19
17	Age-specific mortality rates of anal cancer in Czechia (estimates for 2020)	21
18	Annual number of deaths of of anal cancer in Czechia (estimates for 2020)	21
19	Comparison of age-specific anal cancer incidence and mortality rates among men in Czechia (estimates for 2020)	22
20	Comparison of age-specific anal cancer incidence and mortality rates among women in Czechia (estimates for	
	2020)	22
21	Age-specific incidence rates of vulva cancer in Czechia (estimates for 2020)	 24
21	Annual number of new cases of vulva cancer in Czechia (estimates for 2020)	24 24
23	Age-specific mortality rates of vulva cancer in Czechia (estimates for 2020)	26
24	Annual number of deaths of vulva cancer in Czechia (estimates for 2020)	26
25	Comparison of age-specific vulva cancer incidence and mortality rates in Czechia (estimates for 2020)	27
26	Age-specific incidence rates of vaginal cancer in Czechia (estimates for 2020)	29
27	Annual number of new cases of vaginal cancer in Czechia (estimates for 2020)	29
28	Age-specific mortality rates of vaginal cancer in Czechia (estimates for 2020)	31
29	Annual number of deaths of vaginal cancer in Czechia (estimates for 2020)	31
30	Comparison of age-specific vaginal cancer incidence and mortality rates in Czechia (estimates for 2020)	32
31	Age-specific incidence rates of penile cancer in Czechia (estimates for 2020)	34
32	Annual number of new cases of penile cancer in Czechia (estimates for 2020)	34
	Age-specific mortality rates of penile cancer in Czechia (estimates for 2020)	
33		
34	Annual number of deaths of penile cancer in Czechia (estimates for 2020)	36
35	Comparison of age-specific penile cancer incidence and mortality rates in Czechia (estimates for 2020)	
36	Age-specific incidence rates of oropharyngeal cancer in Czechia (estimates for 2020)	39
37	Annual number of new cases of oropharyngeal cancer in Czechia (estimates for 2020)	39
38	Age-specific mortality rates of oropharyngeal cancer in Czechia (estimates for 2020)	41
39	Annual number of deaths of oropharyngeal cancer in Czechia (estimates for 2020)	41
40	Comparison of age-specific oropharyngeal cancer incidence and mortality rates among men in Czechia (estimates	
	for 2020)	42
41	Comparison of age-specific oropharyngeal cancer incidence and mortality rates among women in Czechia (esti-	
	mates for 2020)	42
42	Age-specific incidence rates of oral cavity cancer in Czechia (estimates for 2020)	44
43	Annual number of new cases of oral cavity cancer in Czechia (estimates for 2020)	44
44	Age-specific mortality rates of oral cavity cancer in Czechia (estimates for 2020)	46
45	Annual number of deaths of oral cavity cancer in Czechia (estimates for 2020)	46
46	Comparison of age-specific oral cavity cancer incidence and mortality rates among men in Czechia (estimates for	
	2020)	47
47	Comparison of age-specific oral cavity cancer incidence and mortality rates among women in Czechia (estimates	
	for 2020)	47
48	Age-specific incidence rates of laryngeal cancer in Czechia (estimates for 2020)	49
49	Annual number of new cases of laryngeal cancer in Czechia (estimates for 2020)	49
49 50	Age-specific mortality rates of laryngeal cancer in Czechia (estimates for 2020)	49 51
	Age-specific mortanty rates of faryngeal cancer in Czechia (estimates for 2020)	51
51		91
52	Comparison of age-specific laryngeal cancer incidence and mortality rates among men in Czechia (estimates for	
	2020)	52

53	Comparison of age-specific laryngeal cancer incidence and mortality rates among women in Czechia (estimates for 2020)	52
54	Crude age-specific HPV prevalence (%) and 95% confidence interval in women with normal cervical cytology in Czechia	54
EE	HPV prevalence among women with normal cervical cytology in Czechia, by study	54 54
55 56	HPV 16 prevalence among women with normal cervical cytology in Czechia, by study	55
56		
57	HPV 16 prevalence among women with low-grade cervical lesions in Czechia, by study	56
58	HPV 16 prevalence among women with high-grade cervical lesions in Czechia, by study	56
59	HPV 16 prevalence among women with invasive cervical cancer in Czechia, by study	57
60	Comparison of the ten most frequent HPV oncogenic types in Czechia among women with and without cervical lesions	58
61	Comparison of the ten most frequent HPV oncogenic types in Czechia among women with invasive cervical	
6 0	cancer by histology	60
62 62	Comparison of the ten most frequent HPV types in anal cancer cases in Europe and the World	69
63	Comparison of the ten most frequent HPV types in AIN 2/3 cases in Europe and the World	69
64	Comparison of the ten most frequent HPV types in cases of vulvar cancer in Europe and the World	72
65	Comparison of the ten most frequent HPV types in VIN 2/3 cases in Europe and the World	72
66	$Comparison \ of \ the \ ten \ most \ frequent \ HPV \ types \ in \ cases \ of \ vaginal \ cancer \ in \ Europe \ and \ the \ World \ \ . \ . \ . \ .$	74
67	Comparison of the ten most frequent HPV types in VaIN 2/3 cases in Europe and the World	74
68	Comparison of the ten most frequent HPV types in cases of penile cancer in Europe and the World	76
69	Comparison of the ten most frequent HPV types in PeIN 2/3 cases in Europe and the World	76
70	Estimated coverage* of cervical cancer screening in Czechia	86
71	HPV vaccination coverage in females by year in Czechia	87
72	HPV vaccination coverage in males by year in Czechia	88
73	Age-standardised incidence rates of cervical cancer of Czechia (estimates for 2020)	90
74	Annual number of new cases of cervical cancer by age group in Czechia (estimates for 2020)	91
75	Comparison of age-specific cervical cancer incidence rates in Czechia, within the region, and the rest of world	92
76	Age-standardised incidence rates of anal cancer of Czechia (estimates for 2020)	93
	Annual number of new cases of anal cancer among men by age group in Czechia (estimates for 2020)	93 94
77		
78	Annual number of new cases of anal cancer among women by age group in Czechia (estimates for 2020)	95
79	Comparison of age-specific anal cancer incidence rates among men by age in Czechia, within the region, and the	
	rest of world	96
80	Comparison of age-specific anal cancer incidence rates among women by age in Czechia, within the region, and	
	the rest of world	97
81	Age-standardised incidence rates of vulva cancer of Czechia (estimates for 2020)	98
82	Annual number of new cases of vulva cancer by age group in Czechia (estimates for 2020)	99
83	$Comparison \ of \ age-specific \ vulva \ cancer \ incidence \ rates \ in \ Czechia, \ within \ the \ region, \ and \ the \ rest \ of \ world \ . \ .$	100
84	Age-standardised incidence rates of vaginal cancer of Czechia (estimates for 2020)	101
85	Annual number of new cases of cervical cancer by age group in Czechia (estimates for 2020)	102
86	Comparison of age-specific vaginal cancer incidence rates in Czechia, within the region, and the rest of world	103
87	Age-standardised incidence rates of penile cancer of Czechia (estimates for 2020)	104
88	Annual number of new cases of penile cancer by age group in Czechia (estimates for 2020)	105
89	Comparison of age-specific penile cancer incidence rates in Czechia, within the region, and the rest of world	106
90	Age-standardised incidence rates of oropharyngeal cancer of Czechia (estimates for 2020)	107
91	Annual number of new cases of oropharyngeal cancer among men by age group in Czechia (estimates for 2020)	108
92	Annual number of new cases of oropharyngeal cancer among women by age group in Czechia (estimates for 2020)	
93	Comparison of age-specific oropharyngeal cancer incidence rates among men by age in Czechia, within the re-	,100
50	gion, and the rest of world	110
94	Comparison of age-specific oropharyngeal cancer incidence rates among women by age in Czechia, within the	110
94	region, and the rest of world	111
~~		111
95	Age-standardised incidence rates of oral cavity cancer of Czechia (estimates for 2020)	112
96	Annual number of new cases of oral cavity cancer among men by age group in Czechia (estimates for 2020)	113
97	Annual number of new cases of oral cavity cancer among women by age group in Czechia (estimates for 2020) .	114
98	Comparison of age-specific oral cavity cancer incidence rates among men by age in Czechia, within the region,	
	and the rest of world	115
99	$Comparison \ of \ age-specific \ or al \ cavity \ cancer \ incidence \ rates \ among \ women \ by \ age \ in \ Czechia, \ within \ the \ region,$	
	and the rest of world	116
100	Age-standardised incidence rates of laryngeal cancer of Czechia (estimates for 2020)	117
101	Annual number of new cases of laryngeal cancer among men by age group in Czechia (estimates for 2020)	118
102	Annual number of new cases of laryngeal cancer among women by age group in Czechia (estimates for 2020)	119
	Comparison of age-specific laryngeal cancer incidence rates among men by age in Czechia, within the region,	
	and the rest of world	120
104	Comparison of age-specific laryngeal cancer incidence rates among women by age in Czechia, within the region,	
	and the rest of world	121
105	Age-standardised mortality rates of cervical cancer of Czechia (estimates for 2020)	

107 108 109 110	Annual number of deaths of cervical cancer by age group in Czechia (estimates for 2020) Comparison of age-specific cervical cancer mortality rates in Czechia, within the region, and the rest of world . Age-standardised mortality rates of anal cancer of Czechia (estimates for 2020) Annual number of deaths of anal cancer among men by age group in Czechia (estimates for 2020)	123 124 125 126 127 128
108 109 110	Age-standardised mortality rates of anal cancer of Czechia (estimates for 2020)	125 126 127
109 110	Annual number of deaths of anal cancer among men by age group in Czechia (estimates for 2020) Annual number of deaths of anal cancer among women by age group in Czechia (estimates for 2020) Comparison of age-specific anal cancer mortality rates among men by age in Czechia, within the region, and the rest of world	126 127
110	Annual number of deaths of anal cancer among women by age group in Czechia (estimates for 2020) Comparison of age-specific anal cancer mortality rates among men by age in Czechia, within the region, and the rest of world	127
	Comparison of age-specific anal cancer mortality rates among men by age in Czechia, within the region, and the rest of world	
	rest of world	128
111	Comparison of age-specific anal cancer mortality rates among women by age in Czechia, within the region, and	128
112	the west of world	
		129
113	Age-standardised mortality rates of vulva cancer of Czechia (estimates for 2020)	130
114	Annual number of deaths of vulva cancer by age group in Czechia (estimates for 2020)	131
115	Comparison of age-specific vulva cancer mortality rates in Czechia, within the region, and the rest of world	132
116	Age-standardised mortality rates of vaginal cancer of Czechia (estimates for 2020)	133
117	Annual number of deaths of cervical cancer by age group in Czechia (estimates for 2020)	134
118	Comparison of age-specific vaginal cancer mortality rates in Czechia, within the region, and the rest of world	135
119	Age-standardised mortality rates of penile cancer of Czechia (estimates for 2020)	136
120	Annual number of new deaths of penile cancer by age group in Czechia (estimates for 2020)	137
121	Comparison of age-specific penile cancer mortality rates in Czechia, within the region, and the rest of world	138
122	Age-standardised mortality rates of oropharyngeal cancer of Czechia (estimates for 2020)	139
123	Annual number of deaths of oropharyngeal cancer among men by age group in Czechia (estimates for 2020)	140
124	Annual number of deaths of oropharyngeal cancer among women by age group in Czechia (estimates for 2020).	141
125	Comparison of age-specific oropharyngeal cancer mortality rates among men by age in Czechia, within the	
	region, and the rest of world	142
126	Comparison of age-specific oropharyngeal cancer mortality rates among women by age in Czechia, within the	
	region, and the rest of world	143
127	Age-standardised mortality rates of oral cavity cancer of Czechia (estimates for 2020)	144
128	Annual number of deaths of oral cavity cancer among men by age group in Czechia (estimates for 2020)	145
129	Annual number of deaths of oral cavity cancer among women by age group in Czechia (estimates for 2020)	146
130	Comparison of age-specific oral cavity cancer mortality rates among men by age in Czechia, within the region,	
	and the rest of world	147
131	Comparison of age-specific oral cavity cancer mortality rates among women by age in Czechia, within the region,	
	and the rest of world	148
132	Age-standardised mortality rates of laryngeal cancer of Czechia (estimates for 2020)	149
133	Annual number of deaths of laryngeal cancer among men by age group in Czechia (estimates for 2020)	150
134	Annual number of deaths of laryngeal cancer among women by age group in Czechia (estimates for 2020)	151
	Comparison of age-specific laryngeal cancer mortality rates among men by age in Czechia, within the region,	
	and the rest of world	152
136	Comparison of age-specific laryngeal cancer mortality rates among women by age in Czechia, within the region,	
	and the rest of world	153

List of Tables

1	Key Statistics
2	Cervical cancer incidence in Czechia (estimates for 2020)
3	Cervical cancer incidence in Czechia by cancer registry
4	Age-standardised incidence rates of cervical cancer in Czechia by histological type and cancer registry 12
5	Cervical cancer mortality in Czechia (estimates for 2020)
6	Premature deaths and disability from cervical cancer in Czechia, Europe and the rest of the world (estimates for
	2019)
7	Anal cancer incidence in Czechia (estimates for 2020)
8	Anal cancer mortality in Czechia (estimates for 2020)
9	Vulva cancer incidence in Czechia (estimates for 2020) 2000000000000000000000000000000000000
10	Vulva cancer mortality in Czechia (estimates for 2020) 22000
11	Variat cancer incidence in Czechia (estimates for 2020) 2200 Vaginal cancer incidence in Czechia (estimates for 2020) 2400
12	Vaginal cancer mortality in Czechia (estimates for 2020) 30
13	Penile cancer incidence in Czechia (estimates for 2020)
14	Penile cancer mortality in Czechia (estimates for 2020)
14	Oropharyngeal cancer incidence in Czechia (estimates for 2020)
	Oropharyngeal cancer mortality in Czechia (estimates for 2020)
16	
17	Oral cavity cancer incidence in Czechia (estimates for 2020)
18	Oral cavity cancer mortality in Czechia (estimates for 2020)
19	Laryngeal cancer incidence in Czechia (estimates for 2020)
20	Laryngeal cancer mortality in Czechia (estimates for 2020) 50
21	Prevalence of HPV16 and HPV18 by cytology in Czechia
22	Type-specific HPV prevalence in women with normal cervical cytology, precancerous cervical lesions and invasive
	cervical cancer in Czechia
23	Type-specific HPV prevalence among invasive cervical cancer cases in Czechia by histology
24	Studies on HPV prevalence among HIV+ women with normal cytology in Czechia
25	Studies on HPV prevalence among anal cancer cases in Czechia (male and female)
26	Studies on HPV prevalence among cases of AIN2/3 in Czechia
27	Studies on HPV prevalence among vulvar cancer cases in Czechia
28	Studies on HPV prevalence among VIN 2/3 cases in Czechia
29	Studies on HPV prevalence among vaginal cancer cases in Czechia
30	Studies on HPV prevalence among VaIN 2/3 cases in Czechia
31	Studies on HPV prevalence among penile cancer cases in Czechia
32	Studies on HPV prevalence among PeIN 2/3 cases in Czechia
33	Studies on HPV prevalence among men in Czechia
34	Studies on HPV prevalence among men from special subgroups in Czechia
35	Studies on oral HPV prevalence among healthy in Czechia
36	Studies on HPV prevalence among cases of oral cavity cancer in Czechia
37	Studies on HPV prevalence among cases of oropharyngeal cancer in Czechia
38	Studies on HPV prevalence among cases of hypopharyngeal or laryngeal cancer in Czechia
39	Factors contributing to cervical carcinogenesis (cofactors) in Czechia
40	Percentage of 15-year-olds who have had sexual intercourse in Czechia
41	Median age at first sex in Czechia
42	Marriage patterns in Czechia
42 43	Average number of sexual partners in Czechia 8
44 45	
45	Main characteristics of cervical cancer screening in Czechia 88 National UDV Improvement in Caschia 89
46	National HPV Immunization programme in Czechia 8 Development of multi-advection in Czechia 9
47	Prevalence of male circumcision in Czechia
48	Prevalence of condom use in Czechia
49	Glossary

1 Introduction




Figure 1: Czechia and Eastern Europe

Information Centre aims to compile and centralise updated data and statistics on human papillomavirus (HPV) and related cancers. This report aims to summarise the data available to fully evaluate the burden of disease in Czechia and to facilitate stakeholders and relevant bodies of decision makers to formulate recommendations on the prevention of cervical cancer and other HPV-related cancers. Data include relevant cancer statistic estimates, epidemiological determinants of cervical cancer such as demographics, socioeconomic factors, risk factors, burden of HPV infection in women and men, cervical screening and immunization practices. The report is structured into the following sections:

Section 2, Demographic and socioeconomic factors. This section summarises the socio-demographic profile of Czechia. For analytical purposes, Czechia is classified in the geographical region of Eastern Europe (Figure 1, lighter blue), which is composed of the following countries: Belarus, Hungary, Republic of Moldova, Poland, Romania, Russian Federation, Slovakia, and Ukraine. Throughout the report, Czechia estimates will be complemented with corresponding regional estimates.

Section 3, Burden of HPV related cancers. This section describes the current burden of invasive cervical cancer and other HPV-related cancers in Czechia ith estimates of prevalence, incidence, and mortality rates. Information in other HPV-related cancers includes other anogenital cancers (anus, vulva, vagina, and penis) and head and neck cancers (oral cavity, oropharyngeal, and larynx).

Section 4, HPV related statistics. This section reports on prevalence of HPV and HPV type-specific distribution in Czechia, in women with normal cytology, precancerous lesions and invasive cervical cancer. In addition, the burden of HPV in other anogenital cancers (anus, vulva, vagina, and penis), head and neck cancers (oral cavity, oropharynx, and larynx) and men are presented.

Section 5, Factors contributing to cervical cancer. This section describes factors that can modify the natural history of HPV and cervical carcinogenesis such as smoking, parity, oral contraceptive use, and co-infection with HIV.

Section 6, Sexual and reproductive health behaviour indicators. This section presents sexual and reproductive behaviour indicators that may be used as proxy measures of risk for HPV infection and anogenital cancers, such as age at first sexual intercourse, average number of sexual partners, and anal intercourse among others.

Section 7, HPV preventive strategies. This section presents preventive strategies that include basic characteristics and performance of cervical cancer screening status, status of HPV vaccine licensure introduction, and recommendations in national immunisation programmes.

Section 8, Protective factors for cervical cancer. This section presents male circumcision and the use of condoms.

2 **Demographic and socioeconomic factors**






Figure 2: Population pyramid of Czechia for 2022

Data accessed on 30 Jul 2022

Please refer to original source for methods of estimation. Year of estimate: 2022

Data Sources: United Nations, Department of Economic and Social Affairs, Population Division (2022). World Population Prospects 2022, Online Edition. [Accessed on July 30, 2022].





Data accessed on 30 Jul 2022

Please refer to original source for methods of estimation. Year of estimate: 2022


Data Sources: United Nations, Department of Economic and Social Affairs, Population Division (2022). World Population Prospects 2022, Online Edition. [Accessed on July 30, 2022].

3 **Burden of HPV related cancers**

HPV is the cause of almost all cervical cancer cases and is responsible for an important fraction of other anogenital and head and neck cancer. Here, we present the most recent estimations on the burden of HPV-associated cancer.

3.1 HPV related cancers incidence

Figure 4: Comparison of HPV related cancers incidence to other cancers in men and women of all ages in Czechia (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods Non-melanoma skin cancer is not included

Rates per 100,000 men per year.

Rates per 100,000 women per year.




Figure 5: Comparison of HPV related cancers incidence to other cancers among men and women 15-44 years of age in Czechia (estimates for 2020)

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

Non-melanoma skin cancer is not included

Rates per 100,000 men per year. Rates per 100,000 women per year.

3.2 HPV related cancers mortality





Figure 6: Comparison of HPV related cancers mortality to other cancers in men and women of all ages in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods Non-melanoma skin cancer is not included

Rates per 100,000 men per year. Rates per 100,000 women per year.



-0.00 0.000.00

0.100.00

0.0

50.0


Annual crude mortality rate per 100,000 Czechia: Female (15-44 years)

100.0

0.05

0.05

0.78



Data accessed on 27 Jan 2021

Vagina*

Thyroid -

Penis*

Testis

Prostate

Multiple myeloma

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods Non-melanoma skin cancer is not included

100.0

Rates per 100,000 men per year. Rates per 100,000 women per year.

Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

50.0

3.3 Cervical cancer

Cancer of the cervix uteri is the 4^{th} most common cancer among women worldwide, with an estimated 604,127 new cases and 341,831 deaths in 2020. Worldwide, mortality rates of cervical cancer are substantially lower than incidence with a ratio of mortality to incidence to 57% (GLOBOCAN 2020). The majority of cases are squamous cell carcinoma followed by adenocarcinomas. (Vaccine 2006, Vol. 24, Suppl 3; Vaccine 2008, Vol. 26, Suppl 10; Vaccine 2012, Vol. 30, Suppl 5; IARC Monographs 2007, Vol. 90)

This section describes the current burden of invasive cervical cancer in Czechia and in comparison to geographic region, including estimates of the annual number of new cases, deaths, incidence, and mortality rates.

3.3.1 Cervical cancer incidence in Czechia

to 44 years in Czechia.

Stats.	
	but 769 new cervical cancer cases are diagnosed annually in Czechia timations for 2020).
(es	initions for 2020).
	rvical cancer ranks * as the 11 th leading cause of female cancer in
Cz	echia.

* Ranking of cervical cancer incidence to other cancers among all women according to highest incidence rates (ranking 1st) excluding non-melanoma skin cancer. Ranking is based on crude incidence rates (actual number of cervical cancer cases). Ranking using age-standardized rate (ASR) may differ.

Indicator	Czechia	Eastern Europe	World
Annual number of new cancer cases	769	32,348	604,127
Uncertainty intervals of new cancer cases [95% UI]	[654-904]	$[31,\!584\!-\!33,\!131]$	[582,031-627,062]
Crude incidence rate ^b	14.1	20.8	15.6
Age-standardized incidence rate ^b	9.32	14.5	13.3
Cumulative risk (%) at 75 years old ^a	0.91	1.42	1.39

Table 2: Cervical cancer incidence in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes. ^b Rates per 100,000 women per year.

Table 3: Cervical cancer incidence in Czechia by cancer registry

Cancer registry ¹	Period	N cases ^a	Crude rate ^b	ASR ^b
National	2008-2012	4995	18.7	12.7

Data accessed on 5 Oct 2018

Please refer to original source (available at http://ci5.iarc.fr/CI5-XI/Default.aspx) ASR: Age-standardized rate, Standardized rates have been estimated using the direct method and the World population as the reference. ^a Accumulated number of cases during the period in the population covered by the corresponding registry.

^a Accumulated number of cases ouring the period in the p






Figure 8: Age-specific incidence rates of cervical cancer in Czechia (estimates for 2020)

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

Data Sources

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].





Data accessed on 27 Jan 2021

For more detailed methods of estimation plea e refer to http://gco.iarc.fr/today/data-sources-methods Data Sources

- For age-standardised incidence rates of cervical cancer of Czechia (estimates for 2020) please refer to Figure 73
- For annual number of new cases of cervical cancer by age group in Czechia (estimates for 2020) please refer to Figure 74
- For comparison of age-specific cervical cancer incidence rates in Czechia, within the region, and • the rest of world please refer to Figure 75

3.3.2 Cervical cancer incidence by histology in Czechia

Table 4: Age-standardised incidence rates of cervical cancer in Czechia by histological type and cancer registry

	registry				
Cancer registry ¹	Period	Squamo	Adeno	Other	Unspec.
National	2008-2012	9.8	1.9	0.3	0.4

Data accessed on 5 Oct 2018

Rates per 100,000 women per year. Standarized rates have been estimated using the direct method and the World population as the references.

Adeno: adeno: adenocarcinoma; Other: Other carcinoma; Squamous: Squamous cell carcinoma; Unspec: Unspecified carcinoma; <u>Data Sources:</u> ¹ Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R and Ferlay J, editors (2017). Cancer Incidence in Five Continents, Vol. XI (electronic version). Lyon: International Agency for Research on Cancer. Available from: http://ci5.iarc.fr, accessed [05 October 2018].




Figure 10: Time trends in cervical cancer incidence in Czechia (cancer registry data)

Data accessed on 28 Aug 2018 ^a Estimated annual percentage change based on the trend variable from the net drift for 25 years, from 1984-2008.

Data Sources:

Ferlay J, Colombet M and Bray F. Cancer Incidence in Five Continents, CI5plus: IARC CancerBase No. 9 [Internet]. Lyon, France: International Agency for Research on Cancer; 2018. Available from: http://ci5

Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: Impact of screening against changes in disease risk factors. eur J Cancer 2013;49:3262-73.

3.3.3 Cervical cancer mortality in Czechia

Key Stats. About 398 cervical cancer deaths occur annually in Czechia are diagnosed annually (estimations for 2020). Cervical cancer ranks* as the 8th leading cause of cancer deaths of female cancer deaths in Czechia. Cervical cancer is the 3rd leading cause of cancer deaths in women aged 15 to 44 years in Czechia.

* Ranking of cervical cancer incidence to other cancers among all women according to highest incidence rates (ranking 1st) excluding non-melanoma skin cancer. Ranking is based on crude incidence rates (actual number of cervical cancer cases). Ranking using age-standardized rate (ASR) may differ.

Indicator	Czechia	Eastern Europe	World
Annual number of deaths	398	15,854	341,831
Uncertainty intervals of mortal- ity cancer cases [95% UI]	[339-468]	[15,373-16,350]	[324,231-360,386]
Crude mortality rate ^b	7.32	10.2	8.84
Age-standardized mortality rate ^b	3.56	6.06	7.25
Cumulative risk (%) at 75 years old ^a	0.39	0.65	0.82

Table 5: Cervical cancer mortality in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
^a Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be Expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes b Rates per 100,000 women per year.




Figure 11: Age-specific mortality rates of cervical cancer in Czechia (estimates for 2020)

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

Data So Perlay J, Brvik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].




Figure 12: Annual number of deaths of cervical cancer in Czechia (estimates for 2020)


Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

- For age-standardised mortality rates of cervical cancer of Czechia (estimates for 2020) please refer to Figure 105
- For annual number of deaths of cervical cancer by age group in Czechia (estimates for 2020) please refer to Figure 106
- For comparison of age-specific cervical cancer mortality rates in Czechia, within the region, and the rest of world please refer to Figure 107

3.3.4 Cervical cancer incidence and mortality comparison in Czechia

Figure 13: Comparison of age-specific cervical cancer incidence and mortality rates in Czechia (estimates for 2020)



Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

Data Sourc

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Table 6: Premature deaths and disability from cervical cancer in Czechia, Europe and the rest of the world (estimates for 2019)

	Czechia		Europe		World	
Indicator	Number	Rate	Number	Rate	Number	Rate
DALYs (95% UI) ^a	11,401	211	824,336	189	8,955,013	232
DALIS (95% 01)	(9,077-14,209)	(168-263)	(726, 198-913, 992)	(166-209)	(7,547,733-9,978,462)	(196-259)
YLLs (95% UI) ^b	11,007	204	793,756	182	8,712,962	226
1 LLS (95% 01)*	(8,760-13,727)	(162-254)	(703,004-877,841)	(161-201)	(7, 365, 279 - 9, 728, 886)	(191-252)
YLDs (95% UI) ^c	394 (262-572)	7 (5-11)	30,580 (21,266-42,064)	7 (5-10)	242,051 (171,644-326,024)	6 (4-8)


Data accessed on 29 Apr 2021

^a DALYs (95% UI): estimated disability adjusted life years (95% uncertainty interval)

 b YLLs (95% UI): years of life lost (95% uncertainty interval)

 c YLDs (95% UI): estimated years lived with disability (95% uncertainty interval) Data Sources:

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222



Data accessed on 29 Apr 2021

YLLs: years of life lost YLDs: years lived with disability

Data Sources: GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222

3.4 Anogenital cancers other than the cervix

Data on HPV role in anogenital cancers other than cervix are limited, but there is an increasing body of evidence strongly linking HPV DNA with cancers of anus, vulva, vagina, and penis. Although these cancers are much less frequent compared to cervical cancer, their association with HPV make them potentially preventable and subject to similar preventative strategies as those for cervical cancer. (Vaccine 2006, Vol. 24, Suppl 3; Vaccine 2008, Vol. 26, Suppl 10; Vaccine 2012, Vol. 30, Suppl 5; IARC Monographs 2007, Vol. 90).

3.4.1 Anal cancer

Anal cancer is rare in the general population with an average worldwide incidence of 1 per 100,000, but is reported to be increasing in more developed regions. Globally, there are an estimated 29,000 new cases in 2018 every year (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Women have higher incidences of anal cancer than men. Incidence is particularly high among populations of men who have sex with men (MSM), women with history of cervical or vulvar cancer, and immunosuppressed populations, including those who are HIV-infected and patients with a history of organ transplantation. These cancers are predominantly squamous cell carcinoma, adenocarcinomas, or basaloid and cloacogenic carcinomas.

3.4.1.1 Anal cancer incidence in Czechia

Table 7: Anal cancer incidence in Czechia (estimates for 2020)				
Indicator	Czechia	Eastern Europe	World	
MEN				
Annual number of new cancer cases	76	900	21,706	
Uncertainty intervals of new cancer cases [95% UI]	[56-103]	[648-1,250]	[18,432-25,561]	
Crude incidence rate ^b	1.44	0.65	0.55	
Age-standardized incidence rate ^b	0.73	0.41	0.49	
Cumulative risk (%) at 75 years old ^a	0.08	0.05	0.06	
WOMEN				
Annual number of new cancer cases	110	1,558	29,159	
Uncertainty intervals of new cancer cases [95% UI]	[59-205]	[1,228-1,977]	[25,656-33,140]	
Crude incidence rate ^c	2.02	1.00	0.75	
Age-standardized incidence rate ^c	0.97	0.50	0.58	
Cumulative risk (%) at 75 years old^a	0.12	0.06	0.07	

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
^a Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes

^b Rates per 100,000 men per year.

^c Rates per 100,000 women per year.

Data Sources:






Figure 15: Age-specific incidence rates of anal cancer in Czechia (estimates for 2020)

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 men per year.

b Rates per 100,000 women per year.

Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for $Research \ on \ Cancer. \ Available \ from: \ \texttt{https://gco.iarc.fr/today} \ , \ accessed \ [27 \ January \ 2021].$





Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods Data Sources

3.4.1.2 Anal cancer mortality in Czechia

Indicator	Czechia	Eastern Europe	World	
MEN				
Annual number of new cancer cases	63	523	9,416	
Uncertainty intervals of new cancer cases [95% UI]	[48-83]	[356-769]	[7,282-12,175]	
Crude incidence rate ^b	1.19	0.38	0.24	
Age-standardized incidence rate ^b	0.55	0.23	0.21	
Cumulative risk (%) at 75 years old ^a	0.07	0.03	0.02	
WOMEN				
Annual number of new cancer cases	59	715	9,877	
Uncertainty intervals of new cancer cases [95% UI]	[44-79]	[515-993]	[7,795-12,516]	
Crude incidence rate ^c	1.09	0.46	0.26	
Age-standardized incidence rate ^c	0.42	0.20	0.19	
Cumulative risk (%) at 75 years old ^a	0.05	0.02	0.02	

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes. ^b Rates per 100,000 men per year. ^c Rates per 100,000 women per year.



Figure 17: Age-specific mortality rates of anal cancer in Czechia (estimates for 2020)

0

15-19 20-24

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 men per year.

25-29 30-34 35-39 40-44


b Rates per 100,000 women per year.


Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for $Research \ on \ Cancer. \ Available \ from: \ \texttt{https://gco.iarc.fr/today} \ , \ accessed \ [27 \ January \ 2021].$

45-49 50-54 55-59 60-64 62-69 70-74 75-79 80-84

85+

Age group (years)





Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods Data Sources

3.4.1.3 Anal cancer incidence and mortality comparison in Czechia






Figure 19: Comparison of age-specific anal cancer incidence and mortality rates among men in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 men per year.

Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].





Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 women per year.

Data Sources:

3.4.2 Vulva cancer

Cancer of the vulva is rare among women worldwide, with an estimated 44,000 new cases in 2018, representing 6% of all gynaecologic cancers (de Martel C et al. Lancet Glob Health 2020;8(2):e180e190). Worldwide, about 60% of all vulvar cancer cases occur in more developed countries. Vulvar cancer has two distinct histological patterns with two different risk factor profiles: (1) basaloid/warty types (2) keratinising types. Basaloid/warty lesions are more common in young women, are very often associated with HPV DNA detection (75-100%), and have a similar risk factor profile as cervical cancer. Keratinising vulvar carcinomas represent the majority of the vulvar lesions (>60%), they occur more often in older women and are more rarely associated with HPV (IARC Monograph Vol 100B).

3.4.2.1 Vulva cancer incidence in Czechia

Table 9: Vulva cancer incidence in Czechia (estimates for 2020)				
Indicator	Czechia	Eastern Europe	World	
Annual number of new cancer cases	276	5,012	45,240	
Uncertainty intervals [95% UI]	[196-390]	[4,689-5,357]	[40,656-50,342]	
Crude incidence rate ^b	5.08	3.23	1.17	
Age-standardized incidence rate ^b	1.97	1.30	0.85	
Cumulative risk (%) at 75 years old ^a	0.22	0.15	0.09	

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

^a Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

^b Rates per 100,000 women per year. <u>Data Sources</u>:






Figure 21: Age-specific incidence rates of vulva cancer in Czechia (estimates for 2020)

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].





Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

3.4.2.2 Vulva cancer mortality in Czechia

Indicator	Czechia	Eastern Europe	World
Annual number of deaths	99	2,561	$17,\!427$
Uncertainty intervals [95% UI]	[70-141]	[2,144-3,059]	[14,497-20,950]
Crude mortality rate ^b	1.82	1.65	0.45
Age-standardized mortality rate ^b	0.54	0.59	0.30
Cumulative risk (%) at 75 years old ^a	0.06	0.06	0.03

Table 10: Vulva cancer mortality in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

Data accessed on 2/Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes. b Rates per 100,000 women per year.






Figure 23: Age-specific mortality rates of vulva cancer in Czechia (estimates for 2020)

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].





Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

Data Sources:

3.4.2.3 Vulva cancer incidence and mortality comparison in Czechia




Figure 25: Comparison of age-specific vulva cancer incidence and mortality rates in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

3.4.3 Vaginal cancer

Cancer of the vagina is a rare cancer, with an estimated 18,000 new cases in 2018, representing 3% of all gynaecologic cancers (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Similar to cervical cancer, the majority of vaginal cancer cases (68%) occur in less developed countries. Most vaginal cancers are squamous cell carcinoma (90%) generally attributable to HPV, followed by clear cell adenocarcinomas and melanoma. Vaginal cancers are primarily reported in developed countries. Metastatic cervical cancer can be misclassified as cancer of the vagina. Invasive vaginal cancer is diagnosed primarily in old women (>= 65 years) and the diagnosis is rare in women under 45 years whereas the peak incidence of carcinoma in situ is observed between ages 55 and 70 (Vaccine 2008, Vol. 26, Suppl 10).

3.4.3.1 Vaginal cancer incidence in Czechia

Indicator	Czechia	Eastern Europe	World
Annual number of new cancer cases	49	1,005	17,908
Uncertainty intervals [95% UI]	[36-67]	[877-1,152]	[14,678-21,848]
Crude incidence rate ^b	0.90	0.65	0.46
Age-standardized incidence rate ^b	0.37	0.31	0.36
Cumulative risk (%) at 75 years old ^a	0.04	0.04	0.04

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

 b Rates per 100,000 women per year. Data Sources






Figure 26: Age-specific incidence rates of vaginal cancer in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for $Research \ on \ Cancer. \ Available \ from: \ \texttt{https://gco.iarc.fr/today} \ , \ accessed \ [27 \ January \ 2021].$





Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

3.4.3.2 Vaginal cancer mortality in Czechia

Indicator	Czechia	Eastern Europe	World
Annual number of deaths	23	485	7,995
Uncertainty intervals [95% UI]	[15-36]	[322-730]	[5,983-10,684]
Crude mortality rate ^b	0.42	0.31	0.21
Age-standardized mortality rate ^b	0.13	0.13	0.16
Cumulative risk (%) at 75 years old ^a	0.01	0.01	0.02

Table 12: Vaginal cancer	mortality in	Czechia	(estimates for 2020)

Data accessed on 27 Jan 2021

Data accessed on 2/Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes. b Rates per 100,000 women per year.






Figure 28: Age-specific mortality rates of vaginal cancer in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for $Research \ on \ Cancer. \ Available \ from: \ \texttt{https://gco.iarc.fr/today} \ , \ accessed \ [27 \ January \ 2021].$





Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods Data Sources:

3.4.3.3 Vaginal cancer incidence and mortality comparison in Czechia




Figure 30: Comparison of age-specific vaginal cancer incidence and mortality rates in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

3.4.4 Penile cancer

The annual burden of penile cancer has been estimated to be 34,000 cases in 2018 worldwide with incidence rates strongly correlating with those of cervical cancer (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Penile cancer is rare and most commonly affects men aged 50-70 years. Incidence rates are higher in less developed countries than in more developed countries, accounting for up to 10% of male cancers in some parts of Africa, South America and Asia. Precursor cancerous penile lesions (PeIN) are rare.

Cancers of the penis are primarily of squamous cell carcinomas (SCC) (95%) and the most common penile SCC histologic sub-types are keratinising (49%), mixed warty-basaloid (17%), verrucous (8%) warty (6%), and basaloid (4%). HPV is most commonly detected in basaloid and warty tumours but is less common in keratinising and verrucous tumours. Approximately 60-100% of PeIN lesions are HPV DNA positive.

3.4.4.1 Penile cancer incidence in Czechia

Table 13: Penile cancer incidence in Czechia (estimates for 2020)			
Indicator	Czechia	Eastern Europe	World
Annual number of new cancer cases	125	2,038	36,068
Uncertainty intervals [95% UI]	[78-200]	[1,828-2,272]	[30, 963 - 42, 015]
Crude incidence rate ^b	2.37	1.48	0.92
Age-standardized incidence rate ^b	1.14	0.91	0.80
Cumulative risk (%) at 75 years old ^a	0.13	0.11	0.09

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

^b Rates per 100,000 men per year. Data Sources






Figure 31: Age-specific incidence rates of penile cancer in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.

Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].





Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

3.4.4.2 Penile cancer mortality in Czechia

Indicator	Czechia	Eastern Europe	World
Annual number of deaths	34	762	13,211
Uncertainty intervals [95% UI]	[24-49]	[551-1,055]	$[10,\!687\!-\!16,\!332]$
Crude mortality rate ^b	0.64	0.55	0.34
Age-standardized mortality rate ^b	0.29	0.33	0.29
Cumulative risk (%) at 75 years old ^a	0.03	0.04	0.03

Table 14: Penile cancer mortality in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

Data accessed on 2/Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes. b Rates per 100,000 men per year.






Figure 33: Age-specific mortality rates of penile cancer in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.

Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for $Research \ on \ Cancer. \ Available \ from: \ \texttt{https://gco.iarc.fr/today} \ , \ accessed \ [27 \ January \ 2021].$





Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

3.4.4.3 Penile cancer incidence and mortality comparison in Czechia




Figure 35: Comparison of age-specific penile cancer incidence and mortality rates in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.

3.5 Head and neck cancers

The majority of head and neck cancers are associated with high tobacco and alcohol consumption. However, increasing trends in the incidence at specific sites suggest that other aetiological factors are involved, and infection by certain high-risk types of HPV (i.e. HPV16) have been reported to be associated with head and neck cancers, in particular with oropharyngeal cancer. Current evidence suggests that HPV16 is associated with tonsil cancer (including Waldeyer ring cancer), base of tongue cancer and other oropharyngeal cancer sites. Associations with other head and neck cancer sites such as oral cancer are neither strong nor consistent when compared to molecular-epidemiological data on HPV and oropharyngeal cancer. Association with laryngeal cancer is still unclear (IARC Monograph Vol 100B)

3.5.1 Oropharyngeal cancer

3.5.1.1 Oropharyngeal cancer incidence in Czechia

Table 15: Oropharyngeal cancer incidence in Czechia (estimates for 2020)			
Indicator	Czechia	Eastern Europe	World
MEN			
Annual number of new cancer cases	378	9,200	79,045
Uncertainty intervals of new cancer cases [95% UI]	[301-475]	[8,757-9,665]	[72,769-85,862]
Crude incidence rate sa ^b	7.17	6.67	2.01
$\begin{array}{c} \mbox{Age-standardized} & \mbox{incidence} & \mbox{rate} \\ \mbox{sa}^{b} \end{array}$	4.00	4.36	1.79
Cumulative risk (%) at 75 years old ^a	0.50	0.54	0.22
WOMEN			
Annual number of new cancer cases	146	1,891	19,367
Uncertainty intervals of new cancer cases [95% UI]	[101-212]	[1,696-2,108]	[16,279-23,041]
Crude incidence rate sa ^c	2.69	1.22	0.50
Age-standardized incidence rate sa ^c	1.37	0.68	0.40
Cumulative risk (%) at 75 years old^a	0.17	0.08	0.05

. .

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
^a Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

^b Rates per 100,000 men per year.

^c Rates per 100,000 women per year.

Data Sources




Figure 36: Age-specific incidence rates of oropharyngeal cancer in Czechia (estimates for 2020)


Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.

^b Rates per 100,000 women per year.

Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for $Research \ on \ Cancer. \ Available \ from: \ \texttt{https://gco.iarc.fr/today} \ , \ accessed \ [27 \ January \ 2021].$

Figure 37: Annual number of new cases of oropharyngeal cancer in Czechia (estimates for 2020)



Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

3.5.1.2 Oropharyngeal cancer mortality in Czechia

Czechia	Eastern Europe	World
169	4,925	39,590
[133-215]	[4,331-5,601]	[35,255-44,458]
3.21	3.57	1.01
1.82	2.31	0.89
0.22	0.29	0.11
47	710	8,553
[34-65]	[506-996]	[6,684-10,945]
0.86	0.46	0.22
0.39	0.23	0.17
0.05	0.03	0.02
	169 [133-215] 3.21 1.82 0.22 47 [34-65] 0.86 0.39	$\begin{array}{ c c c c c c }\hline & & & & & & & & & & & & & & & & & & &$

Table 16: Oronhamungoal cancer mortality in Czochia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

^b Rates per 100,000 men per year. ^c Rates per 100,000 women per year.




Figure 38: Age-specific mortality rates of oropharyngeal cancer in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021


For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 men per year.

^b Rates per 100,000 women per year

Data Sources

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 39: Annual number of deaths of oropharyngeal cancer in Czechia (estimates for 2020)




Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

3.5.1.3 Oropharyngeal cancer incidence and mortality comparison in Czechia

Figure 40: Comparison of age-specific oropharyngeal cancer incidence and mortality rates among men in Czechia (estimates for 2020)




Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 men per year. Data Sources

Farlay J. Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Figure 41: Comparison of age-specific oropharyngeal cancer incidence and mortality rates among women in Czechia (estimates for 2020)



Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 women per year. Data Sources

3.5.2 Oral cavity cancer

3.5.2.1 Oral cavity cancer incidence in Czechia

Indicator	Czechia	Eastern Europe	World
MEN			
Annual number of new cancer cases	572	19,884	264,211
Uncertainty intervals of new cancer cases [95% UI]	[483-677]	[19,288-20,498]	[251,153- 277,948]
Crude incidence rate sa ^b	10.8	14.4	6.72
Age-standardized incidence rate sa ^b	5.98	9.22	5.96
Cumulative risk (%) at 75 years old^a	0.73	1.12	0.68
WOMEN			
Annual number of new cancer cases	319	6,199	113,502
Uncertainty intervals of new cancer cases [95% UI]	[250-407]	[5,864-6,553]	[105,599- 121,997]
Crude incidence rate sa ^c	5.87	3.99	2.94
Age-standardized incidence rate sa ^c	2.78	1.87	2.28
Cumulative risk (%) at 75 years old ^a	0.33	0.21	0.26

Table 17. Oral o vity o incide a in Crachia (actimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes. ^b Rates per 100,000 men per year. ^c Rates per 100,000 women per year.




Figure 42: Age-specific incidence rates of oral cavity cancer in Czechia (estimates for 2020)


Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.

^b Rates per 100,000 women per year.

Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for $Research \ on \ Cancer. \ Available \ from: \ \texttt{https://gco.iarc.fr/today} \ , \ accessed \ [27 \ January \ 2021].$

Figure 43: Annual number of new cases of oral cavity cancer in Czechia (estimates for 2020)



Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods Data Sources:

3.5.2.2 Oral cavity cancer incidence and mortality comparison in Czechia

Table 18: Oral cavity cancer mortality in Czechia (estimates for 2020)			
Indicator	Czechia	Eastern Europe	World
MEN			
Annual number of deaths	227	9,761	125,022
Uncertainty intervals of mortality	[181-285]	[8,901-10,704]	[116,573-
cancer cases [95% UI]	[101-200]	[0,901-10,704]	134,084]
Crude mortality rate sa ^b	4.31	7.08	3.18
Age-standardized mortality rate sa ^b	2.28	4.54	2.82
Cumulative risk (%) at 75 years old^a	0.29	0.56	0.32
WOMEN			
Annual number of deaths	134	2,729	52,735
Uncertainty intervals of mortality	[97-185]	[2,286-3,258]	[47,690-58,313]
cancer cases [95% UI]	[37-100]	[2,200-0,200]	[41,000-00,010]
Crude mortality rate sa ^c	2.46	1.76	1.36
Age-standardized mortality rate sa ^c	1.07	0.82	1.04
Cumulative risk (%) at 75 years old^a	0.12	0.09	0.12

T-11 10. **O**-1 - -----1:4 : O - - - his (anti-C 0000)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
^a Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be
expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

^b Rates per 100,000 men per year. ^c Rates per 100,000 women per year.




Figure 44: Age-specific mortality rates of oral cavity cancer in Czechia (estimates for 2020)


Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.

^b Rates per 100,000 women per year.

Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for $Research \ on \ Cancer. \ Available \ from: \ \texttt{https://gco.iarc.fr/today} \ , \ accessed \ [27 \ January \ 2021].$

Figure 45: Annual number of deaths of oral cavity cancer in Czechia (estimates for 2020)



Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

3.5.2.3 Oral cavity cancer incidence and mortality comparison in Czechia






Figure 46: Comparison of age-specific oral cavity cancer incidence and mortality rates among men in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 men per year. Data Sources:

Ferlay J. Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].





Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 women per year.

3.5.3 Laryngeal cancer

3.5.3.1 Laryngeal cancer incidence in Czechia

Indicator	Czechia	Eastern Europe	World
MEN			
Annual number of new cancer cases	428	16,580	160,265
Uncertainty intervals of new cancer cases [95% UI]	[356-515]	[16,000-17,181]	[150,633- 170,513]
Crude incidence rate sa ^b	8.12	12.0	4.08
Age-standardized incidence rate sa^b	4.27	7.58	3.59
Cumulative risk (%) at 75 years old^a	0.56	0.97	0.45
WOMEN			
Annual number of new cancer cases	72	1,550	24,350
Uncertainty intervals of new cancer cases [95% UI]	[55-95]	[1,367-1,757]	[20,845-28,444]
Crude incidence rate sa ^c	1.32	1.00	0.63
Age-standardized incidence rate sa ^c	0.60	0.53	0.49
Cumulative risk (%) at 75 years old ^a	0.08	0.07	0.06

ngeal cancer incidence in Czechia (estimates for 2020) Table 10. Law

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Cumulative risk (incidence) is the probability or risk of individuals getting from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to develop from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes. ^b Rates per 100,000 men per year. ^c Rates per 100,000 women per year.




Figure 48: Age-specific incidence rates of laryngeal cancer in Czechia (estimates for 2020)


Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.

^b Rates per 100,000 women per year.

Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for $Research \ on \ Cancer. \ Available \ from: \ \texttt{https://gco.iarc.fr/today} \ , \ accessed \ [27 \ January \ 2021].$

Figure 49: Annual number of new cases of laryngeal cancer in Czechia (estimates for 2020)



Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

3.5.3.2 Laryngeal cancer incidence and mortality comparison in Czechia

Table 20: Laryngeal cancer mortality in Czechia (estimates for 2020)			
Indicator	Czechia	Eastern Europe	World
MEN			
Annual number of deaths	217	9,518	85,351
Uncertainty intervals of mortality cancer cases [95% UI]	[178-265]	[9,130-9,923]	[78,895-92,335]
Crude mortality rate sa ^b	4.12	6.91	2.17
Age-standardized mortality rate sa ^b	2.19	4.26	1.89
Cumulative risk (%) at 75 years old ^a	0.27	0.55	0.23
WOMEN			
Annual number of deaths	30	741	14,489
Uncertainty intervals of mortality cancer cases [95% UI]	[20-45]	[633-868]	[11,902-17,639]
Crude mortality rate sa ^c	0.55	0.48	0.37
Age-standardized mortality rate sa ^c	0.21	0.24	0.28
Cumulative risk (%) at 75 years old^a	0.03	0.03	0.03

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Cumulative risk (mortality) is the probability or risk of individuals dying from the disease during ages 0-74 years. For cancer, it is expressed as the % of new born children who would be expected to die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of competing causes.

^b Rates per 100,000 men per year.
 ^c Rates per 100,000 women per year.




Figure 50: Age-specific mortality rates of laryngeal cancer in Czechia (estimates for 2020)


Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.

^b Rates per 100,000 women per year.


Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for $Research \ on \ Cancer. \ Available \ from: \ \texttt{https://gco.iarc.fr/today} \ , \ accessed \ [27 \ January \ 2021].$


Figure 51: Annual number of deaths of of laryngeal cancer in Czechia (estimates for 2020)



Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods

3.5.3.3 Laryngeal cancer incidence and mortality comparison in Czechia







Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 men per year. Data Sources

Farlay J. Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].





Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 women per year. Data Sources

4 HPV related statistics

HPV infection is commonly found in the anogenital tract of men and women with and without clinical lesions. The aetiological role of HPV infection among women with cervical cancer is well-established, and there is growing evidence of its central role in other anogenital sites. HPV is also responsible for other diseases such as recurrent juvenile respiratory papillomatosis and genital warts, both mainly caused by HPV types 6 and 11 (Lacey CJ, Vaccine 2006; 24(S3):35). For this section, the methodologies used to compile the information on HPV burden are derived from systematic reviews and meta-analyses of the literature. Due to the limitations of HPV DNA detection methods and study designs used, these data should be interpreted with caution and used only as a guide to assess the burden of HPV infection within the population. (Vaccine 2006, Vol. 24, Suppl 3; Vaccine 2008, Vol. 26, Suppl 10; Vaccine 2012,Vol. 30, Suppl 5; IARC Monographs 2007, Vol. 90).

4.1 HPV burden in women with normal cervical cytology, cervical precancerous lesions or invasive cervical cancer


The statistics shown in this section focus on HPV infection in the cervix uteri. HPV cervical infection results in cervical morphological lesions ranging from normalcy (cytologically normal women) to different stages of precancerous lesions (CIN-1, CIN-2, CIN-3/CIS) and invasive cervical cancer. HPV infection is measured by HPV DNA detection in cervical cells (fresh tissue, paraffin embedded or exfoliated cells). The prevalence of HPV increases with lesion severity. HPV causes virtually 100% of cervical cancer cases, and an underestimation of HPV prevalence in cervical cancer is most likely due to the limitations of study methodologies. Worldwide, HPV16 and 18 (the two vaccine-preventable types) contribute to over 70% of all cervical cancer cases, between 41% and 67% of high-grade cervical lesions and 16-32% of low-grade cervical lesions. After HPV16/18, the six most common HPV types are the same in all world regions, namely 31, 33, 35, 45, 52 and 58; these account for an additional 20% of cervical cancers worldwide (Clifford G, Vaccine 2006;24(S3):26).

Methods: Prevalence and type distribution of human papillomavirus in cervical carcinoma, low-grade cervical lesions, high-grade cervical lesions and normal cytology: systematic review and meta-analysis

A systematic review of the literature was conducted regarding the worldwide HPV-prevalence and type distribution for cervical carcinoma, low-grade cervical lesions, high-grade cervical lesions and normal cytology from 1990 to 'data as of' indicated in each section. The search terms for the review were 'HPV' AND cerv* using Pubmed. There were no limits in publication language. References cited in selected articles were also investigated. Inclusion criteria were: HPV DNA detection by means of PCR or HC2, a minimum of 20 cases for cervical carcinoma, 20 cases for low-grade cervical lesions, 20 cases for highgrade cervical lesions and 100 cases for normal cytology and a detailed description of HPV DNA detection and genotyping techniques used. The number of cases tested and HPV positive extracted for each study were pooled to estimate the prevalence of HPV DNA and the HPV type distribution globally and by geographical region. Binomial 95% confidence intervals were calculated for each HPV prevalence. For more details refer to the methods document.

4.1.1 HPV prevalence in women with normal cervical cytology

Figure 54: Crude age-specific HPV prevalence (%) and 95% confidence interval in women with normal cervical cytology in Czechia



Data updated on 30 Jun 2015 (data as of 30 Jun 2014)

Data Sources: Tachezy R, PLoS ONE 2013; 8: e79156

Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until June 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453

Figure 55: HPV prevalence among women with normal cervical cytology in Czechia, by study



Data updated on 30 Jun 2015 (data as of 30 Jun 2014)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells) $^a\,$ Number of women tested

Data Sources: Tachezy R, PLoS ONE 2013; 8: e79156

Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until June 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453

4.1.2 HPV type distribution among women with normal cervical cytology, precancerous cervical lesions and cervical cancer

	No. tested	HPV 16/18 Prevalence % (95% CI)
Normal cytology ^{1,2}	1302	6.6 (5.4-8.1)
Low-grade lesions ^{3,4}	676	33.7 (30.3-37.4)
High-grade lesions ^{5,6}	311	63.3 (57.9-68.5)
Cervical cancer ^{7,8}	270	79.3 (74.0-83.7)

Table 21: Prevalence of HPV16 and HPV18 by cytology in Czechia

Data updated on 19 May 2017 (data as of 30 Jun 2015 / 30 Nov 2014)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)

Number of women tested ^b 95% Confidence Interval

Data Sources

¹ Tachezy R, PLoS ONE 2013; 8: e79156

² Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until November 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453

 3 Contributing studies: Tachezy R, PLoS ONE 2011; 6: e21913

⁴ Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Clifford GM, Cancer Epidemiol Biomarkers Prev 2005;14:1157

⁵ Contributing studies: Tachezy R, PLoS ONE 2011; 6: e21913

6 Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Smith JS, Int J Cancer 2007;121:621 3) Clifford GM, Br J Cancer 2003;89:101.

⁷ Contributing studies: Slama J, Int J Gynecol Cancer 2009; 19: 703 | Tachezy R, J Med Virol 1999; 58: 378 | Tachezy R, PLoS ONE 2011; 6: e21913

⁸ Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Li N, Int J Cancer 2011;128:927 3) Smith JS, Int J Cancer 2007;121:621 4) Clifford GM, Br J Cancer 2003;88:63 5) Clifford GM, Br J Cancer 2003;89:101.

Figure 56: HPV 16 prevalence among women with normal cervical cytology in Czechia, by study

·•	
0%	10%

Data updated on 30 Jun 2015 (data as of 30 Jun 2014)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells) $^a\,$ Number of women tested

Data Sources: Tachezy R, PLoS ONE 2013; 8: e79156

Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until June 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453

Figure 57: HPV 16 prevalence among women with low-grade cervical lesions in Czechia, by study

		Study y 2011 6% 28% (25%-S1).9)
20%	30%	40%

Data updated on 27 Jan 2017 (data as of 30 Jun 2015)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)

^a Number of women tested Data Sources:

Tachezy R, PLoS ONE 2011; 6: e21913 Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Refer-ence publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Clifford GM, Cancer Epidemiol Biomarkers Prev 2005;14:1157

Figure 58: HPV 16 prevalence among women with high-grade cervical lesions in Czechia, by study

		Study 2011 3 H 1 582 (95.7-63.5)
50%	60%	70%
0070		

Data updated on 27 Jan 2017 (data as of 30 Jun 2015)


The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells) a Number of women tested

Data Sources:

Tachezy R, PLoS ONE 2011; 6: e21913

Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Smith JS, Int J Cancer 2007;121:621 3) Clifford GM, Br J Cancer 2003;89:101.

Figure 59: HPV 16 prevalence among women with invasive cervical cancer in Czechia, by study



Data updated on 19 May 2017 (data as of 30 Jun 2015)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells) a Number of women tested

Data Sources: Slama J, Int J Gynecol Cancer 2009; 19: 703 | Tachezy R, J Med Virol 1999; 58: 378 | Tachezy R, PLoS ONE 2011; 6: e21913 Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Refer-ence publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Li N, Int J Cancer 2011;128:927 3) Smith JS, Int J Cancer 2007;121:621 4) Clifford GM, Br J Cancer 2003;88:63 5) Clifford GM, Br J Cancer 2003;89:101.




Figure 60: Comparison of the ten most frequent HPV oncogenic types in Czechia among women with and without cervical lesions

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

Data Sources:

¹ Contributing studies: Slama J, Int J Gynecol Cancer 2009; 19: 703 | Tachezy R, J Med Virol 1999; 58: 378 | Tachezy R, PLoS ONE 2011; 6: e21913

² Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Li N, Int J Cancer 2011;128:927 3) Smith JS, Int J Cancer 2007;121:621 4) Clifford GM, Br J Cancer 2003;88:63 5) Clifford GM, Br J Cancer 2003;89:101. ³ Contributing studies: Tachezy R, PLoS ONE 2011; 6: e21913

Contributing studies. Fachezy R, FLOS ONE 2011, 0. 62216
 ⁴ Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015.
 Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Smith JS, Int J Cancer 2007;121:621 3) Clifford GM, Br J Cancer 2003;89:101.

⁵ Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Clifford GM, Cancer Epidemiol Biomarkers Prev 2005;14:1157
⁶ Tachezy R, PLoS ONE 2013; 8: e79156
⁷ Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until November 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453




Figure 61: Comparison of the ten most frequent HPV oncogenic types in Czechia among women with invasive cervical cancer by histology

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

 * No data available. No more types than shown were tested or were positive

Data Sources:

² Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2014. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Li N, Int J Cancer 2011;128:927 3) Smith JS, Int J Cancer 2007;121:621 4) Clifford GM, Br J Cancer 2003;88:63 5) Clifford GM, Br J Cancer 2003;89:101.

³ Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Li N, Int J Cancer 2011;128:927 3) Smith JS, Int J Cancer 2007;121:621 4) Clifford GM, Br J Cancer 2003;88:63 5) Clifford GM, Br J Cancer 2003;89:101.

¹Contributing studies: Slama J, Int J Gynecol Cancer 2009; 19: 703 | Tachezy R, J Med Virol 1999; 58: 378 | Tachezy R, PLoS ONE 2011; 6: e21913

lesions and invasive cervical cancer in Czechia								
			Low-g	Low-grade lesions ^{3,4} High-grade lesions ^{5,6}		grade lesions ^{5,6}	Cervical cancer ^{7,8}	
HPV	No.	HPV Prev %	No.	HPV Prev %	No.	HPV Prev %	No.	HPV Prev %
Туре	tested	(95% CI)	tested	(95% CI)	tested	(95% CI)	tested	(95% CI)
	ENIC HPV							
High-r	isk HPV ty							
16	1302	4.8 (3.8-6.1)	676	28.4 (25.1-31.9)	311	58.2 (52.7-63.5)	270	68.5 (62.8-73.8)
18	1302	1.8 (1.2-2.7)	676	5.3(3.9-7.3)	311	5.1(3.2-8.2)	270	10.7 (7.6-15.0)
31	1302	1.2 (0.8-2.0)	676	4.3 (3.0-6.1)	311	12.2 (9.0-16.3)	221	6.3 (3.8-10.4)
33	1302	1.3 (0.8-2.1)	676	6.8 (5.1-9.0)	311	13.2 (9.9-17.4)	221	8.1 (5.2-12.5)
35	1302	0.4 (0.2-0.9)	676	3.0 (1.9-4.5)	311	1.6 (0.7-3.7)	221	0.0 (0.0-1.7)
39	1302	2.0 (1.4-2.9)	676	0.3 (0.1-1.1)	311	0.6 (0.2-2.3)	221	1.8 (0.7-4.6)
45	1302	2.0 (1.4-2.9)	676	4.7 (3.4-6.6)	311	4.2 (2.5-7.0)	221	7.7 (4.9-12.0)
51	1302	1.6 (1.1-2.5)	676	3.8 (2.6-5.6)	311	2.3 (1.1-4.6)	221	0.0 (0.0-1.7)
52	1302	1.3 (0.8-2.1)	676	2.1 (1.2-3.4)	311	3.2 (1.8-5.8)	221	0.9 (0.2-3.2)
56	1302	2.4 (1.7-3.4)	676	3.6 (2.4-5.2)	311	3.2 (1.8-5.8)	221	1.8 (0.7-4.6)
58	1302	0.8 (0.5-1.5)	676	4.4 (3.1-6.3)	311	4.5 (2.7-7.4)	221	3.2 (1.5-6.4)
59	1302	0.7 (0.4-1.3)	676	0.9 (0.4-1.9)	311	0.0 (0.0-1.2)	221	0.0 (0.0-1.7)
		e carcinogen						
26	1302	0.1 (0.0-0.4)	676	0.3 (0.1-1.1)	311	0.3 (0.1-1.8)	221	0.0 (0.0-1.7)
30	-	-	338	0.0 (0.0-1.1)	311	0.0 (0.0-1.2)	135	0.0 (0.0-2.8)
34	-	-	338	0.0 (0.0-1.1)	311	0.0 (0.0-1.2)	135	0.0 (0.0-2.8)
53	1302	1.9 (1.3-2.8)	676	0.0 (0.0-0.6)	311	0.3 (0.1-1.8)	221	0.9 (0.2-3.2)
66	1302	0.5 (0.2-1.0)	676	1.8 (1.0-3.1)	311	1.6 (0.7-3.7)	221	0.0 (0.0-1.7)
67	1302	0.2 (0.1-0.7)	338	0.0 (0.0-1.1)	311	0.0 (0.0-1.2)	135	0.0 (0.0-2.8)
68	1302	1.2 (0.8-2.0)	676	0.6 (0.2-1.5)	311	0.0 (0.0-1.2)	221	0.0 (0.0-1.7)
69	-	-	338	0.0 (0.0-1.1)	311	0.0 (0.0-1.2)	135	0.0 (0.0-2.8)
70	1302	0.9 (0.5-1.6)	676	1.5(0.8-2.7)	311	0.6 (0.2-2.3)	221	0.0 (0.0-1.7)
73	1302	0.5 (0.3-1.1)	676	0.0 (0.0-0.6)	311	0.0 (0.0-1.2)	221	1.4 (0.5-3.9)
82	1302	0.7 (0.4-1.3)	676	0.0 (0.0-0.6)	311	1.3(0.5-3.3)	221	0.0 (0.0-1.7)
85	-	-	338	0.0 (0.0-1.1)	311	0.0 (0.0-1.2)	-	-
97	-	-	-	-	-	-	-	-
LOW RIS	SK HPV TY	PES						
6	1302	1.5 (0.9-2.3)	676	4.1 (2.9-5.9)	311	1.0 (0.3-2.8)	172	0.0 (0.0-2.2)
11	1302	0.2 (0.0-0.6)	676	2.4 (1.5-3.8)	311	0.3 (0.1-1.8)	172	0.0 (0.0-2.2)
32	1302	0.1 (0.0-0.4)	338	0.0 (0.0-1.1)	-	-	135	0.0 (0.0-2.8)
40	1302	0.4 (0.2-0.9)	338	0.3 (0.1-1.7)	311	0.0 (0.0-1.2)	135	0.0 (0.0-2.8)
42	1302	2.8 (2.0-3.8)	338	2.1 (1.0-4.2)	311	1.0 (0.3-2.8)	135	0.0 (0.0-2.8)
43	1302	0.2 (0.0-0.6)	338	0.6 (0.2-2.1)	311	0.3 (0.1-1.8)	135	0.0 (0.0-2.8)
44	1302	1.2 (0.8-2.0)	338	0.0 (0.0-1.1)	311	0.3 (0.1-1.8)	135	0.0 (0.0-2.8)
54	1302	1.5 (1.0-2.4)	338	0.9 (0.3-2.6)	311	0.6 (0.2-2.3)	135	0.0 (0.0-2.8)
55	-	-	-	-	-	-	-	-
57	-	-	338	0.0 (0.0-1.1)	311	0.0 (0.0-1.2)	135	0.0 (0.0-2.8)
61	1302	0.7 (0.4-1.3)	338	0.0 (0.0-1.1)	311	0.0 (0.0-1.2)	135	0.0 (0.0-2.8)
62	1302	0.2 (0.0-0.6)	338	0.0 (0.0-1.1)	311	0.0 (0.0-1.2)	135	0.0 (0.0-2.8)
64	-	-	-	-	-	-	-	-
71	-	-	338	0.3 (0.1-1.7)	311	0.0 (0.0-1.2)	135	0.0 (0.0-2.8)
72	1302	0.0 (0.0-0.3)	338	0.0 (0.0-1.1)	311	0.0 (0.0-1.2)	135	0.0 (0.0-2.8)
74	1302	0.3 (0.1-0.8)	338	0.0 (0.0-1.1)	311	0.0 (0.0-1.2)	135	0.0 (0.0-2.8)
81	1302	0.3 (0.1-0.8)	338	1.2 (0.5-3.0)	311	0.6 (0.2-2.3)	135	0.0 (0.0-2.8)
83	-	-	338	0.0 (0.0-1.1)	311	0.0 (0.0-1.2)	135	0.0 (0.0-2.8)
84	-	-	338	0.0 (0.0-1.1)	311	0.0 (0.0-1.2)	135	0.0 (0.0-2.8)
86	-	-	-	-	-	-	-	-
87	-	-	338	0.0 (0.0-1.1)	-	-	-	-
89	-	-	338	0.9 (0.3-2.6)	311	0.0 (0.0-1.2)	135	0.0 (0.0-2.8)
90	1302	0.2 (0.0-0.6)	338	0.0 (0.0-1.1)	-	-	135	0.0 (0.0-2.8)

Table 22: Type-specific HPV prevalence in women with no	ormal cervical cytology, precancerous cervical
lesions and invasive cervical c	ancer in Czechia

Data updated on 30 Jun 2015 (data as of 30 Jun 2015 / 30 Nov 2014)

-

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells)

91

Data Sources: ¹ Tachezy R, PLoS ONE 2013; 8: e79156

² Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until November 2014. Reference publications: 1) Bruni L, J Infect Dis 2010; 202: 1789. 2) De Sanjosé S, Lancet Infect Dis 2007; 7: 453

-

-

0.0 (0.0-1.1)

135

0.0 (0.0-2.8)

 3 Contributing studies: Tachezy R, PLoS ONE 2011; 6: e21913

4 Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Clifford GM, Cancer Epidemiol Biomarkers Prev 2005;14:1157

⁵ Contributing studies: Tachezy R, PLoS ONE 2011; 6: e21913

6 Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Smith JS, Int J Cancer 2007;121:621 3) Clifford GM, Br J Cancer 2003;89:101.

⁷ Contributing studies: Slama J, Int J Gynecol Cancer 2009; 19: 703 | Tachezy R, J Med Virol 1999; 58: 378 | Tachezy R, PLoS ONE 2011; 6: e21913

338

⁸ Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Li N, Int J Cancer 2011;128:927 3) Smith JS, Int J Cancer 2007;121:621 4) Clifford GM, Br J Cancer 2003;88:63 5) Clifford GM, Br J Cancer 2003;89:101.

Table 23: Type-specific HPV		

Table 2	23: Type	-specific HPV p	revalence	e among invasiv	ve cervica	l cancer cases i	in Czechia	a by histology	
	An	y Histology	Squamo	us cell carcinoma	Ade	nocarcinoma	· · · · ·		
HPV	No.	HPV Prev %	No.	HPV Prev %	No.	HPV Prev %	No.	HPV Prev %	
Туре	tested	(95% CI)	tested	(95% CI)	tested	(95% CI)	tested	(95% CI)	
	ENIC HPV								
	isk HPV ty								
16	270	68.5 (62.8-73.8)	172	73.3 (66.2-79.3)	-	-	98	60.2 (50.3-69.3)	
18	270	10.7 (7.6-15.0)	172	9.3 (5.8-14.6)	-	-	98	13.3 (7.9-21.4)	
31	221	6.3 (3.8-10.4)	172	7.0 (4.0-11.8)	-	-	49	4.1 (1.1-13.7)	
33	221	8.1 (5.2-12.5)	172	10.5 (6.7-15.9)	-	-	49	0.0 (0.0-7.3)	
35	221	0.0 (0.0-1.7)	172	0.0 (0.0-2.2)	-	-	49	0.0 (0.0-7.3)	
39	221	1.8 (0.7-4.6)	172	1.2 (0.3-4.1)	-	-	49	4.1 (1.1-13.7)	
45	221	7.7 (4.9-12.0)	172	9.3 (5.8-14.6)	-	-	49	2.0 (0.4-10.7)	
51	221	0.0 (0.0-1.7)	172	0.0 (0.0-2.2)	-	-	49	0.0 (0.0-7.3)	
52	221	0.9 (0.2-3.2)	172	1.2 (0.3-4.1)	-	-	49	0.0 (0.0-7.3)	
56	221	1.8 (0.7-4.6)	172	2.3 (0.9-5.8)	-	-	49	0.0 (0.0-7.3)	
58	221	3.2(1.5-6.4)	172	3.5(1.6-7.4)	-	-	49	2.0 (0.4-10.7)	
59	221	0.0 (0.0-1.7)	172	0.0 (0.0-2.2)	-	-	49	0.0 (0.0-7.3)	
Probab	ole/possible	e carcinogen							
26	221	0.0 (0.0-1.7)	-	-	-	-	-	-	
30	135	0.0 (0.0-2.8)	86	0.0 (0.0-4.3)	-	-	49	0.0 (0.0-7.3)	
34	135	0.0 (0.0-2.8)	86	0.0 (0.0-4.3)	-	-	49	0.0 (0.0-7.3)	
53	221	0.9 (0.2-3.2)	-	-	-	-	-	-	
66	221	0.0 (0.0-1.7)	172	0.0 (0.0-2.2)	-	-	49	0.0 (0.0-7.3)	
67	135	0.0 (0.0-2.8)	86	0.0 (0.0-4.3)	-	-	49	0.0 (0.0-7.3)	
68	221	0.0 (0.0-1.7)	172	0.0 (0.0-2.2)	-	-	49	0.0 (0.0-7.3)	
69	135	0.0 (0.0-2.8)	-	-	-	-	-	-	
70	221	0.0 (0.0-1.7)	-	-	-	-	-	-	
73	221	1.4 (0.5-3.9)	-	-	-	-	-	-	
82	221	0.0 (0.0-1.7)	172	0.0 (0.0-2.2)	-	-	49	0.0 (0.0-7.3)	
85	-	-	-	-	-	-	-	-	
97	-	-	-	-	-	-	-	-	
LOW RIS	SK HPV TY	PES							
6	172	0.0 (0.0-2.2)	-	-		-		-	
11	172	0.0 (0.0-2.2)	-	-	-	-	-	-	
32	135	0.0 (0.0-2.8)	-	-	-	-	-	-	
40	135	0.0 (0.0-2.8)	-	-	-	-	-	-	
42	135	0.0 (0.0-2.8)	86	0.0 (0.0-4.3)	-	-	49	0.0 (0.0-7.3)	
43	135	0.0 (0.0-2.8)	-	-	-	-	-	-	
44	135	0.0 (0.0-2.8)	86	0.0 (0.0-4.3)	-	-	49	0.0 (0.0-7.3)	
54	135	0.0 (0.0-2.8)	-	-	-	-		-	
55		-		-	-	-		-	
57	135	0.0 (0.0-2.8)	-	-	-	-		-	
61	135	0.0 (0.0-2.8)			-	-		-	
62	135	0.0 (0.0-2.8)	-	-	-	-		-	
64	- 100	-	-	-	-	-	-	-	
71	135	0.0 (0.0-2.8)	-	-	-	-	-	-	
72	135	0.0 (0.0-2.8)	-	-	-	-		-	
74	135	0.0 (0.0-2.8)		_	_	-	-	-	
81	135	0.0 (0.0-2.8)	-	_	-	-	-	-	
83	135	0.0 (0.0-2.8)	-			-		-	
84	135	0.0 (0.0-2.8)				-			
86	- 155	-	-	-	-	-			
87		-	-	-		-	-	-	
87	- 135	0.0 (0.0-2.8)	-	-	-	-			
90	135	0.0 (0.0-2.8)	-	-	-	-		-	
90	135	0.0 (0.0-2.8)		-		-		-	
91	199	0.0 (0.0-2.8)		-		-		-	

Data updated on 19 May 2017 (data as of 30 Jun 2015)

The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells) a Number of women tested b 95% Confidence Interval

⁹ 95% Contidence Interval <u>Data Sources</u>: Contributing studies: Slama J, Int J Gynecol Cancer 2009; 19: 703 | Tachezy R, J Med Virol 1999; 58: 378 | Tachezy R, PLoS ONE 2011; 6: e21913 Based on meta-analysis performed by IARC's Infections and Cancer Epidemiology Group up to November 2011, the ICO HPV Information Centre has updated data until June 2015. Refer-ence publications: 1) Guan P, Int J Cancer 2012;131:2349 2) Li N, Int J Cancer 2011;128:927 3) Smith JS, Int J Cancer 2007;121:621 4) Clifford GM, Br J Cancer 2003;88:63 5) Clifford GM, Br J Cancer 2003;89:101.

4.1.3 HPV type distribution among HIV+ women with normal cervical cytology

Table 24: Studies on HPV prevalence among HIV+ women with normal cytology in Czechia

	HPV Prevalence							
Study	HPV detection method and targeted HPV types	No. Tested ^a	%	(95% CI) ^b	Prevalence of 5 most frequent HPVs, HPV type (%)			
-	-	-	-	-				

Data updated on 31 Dec 2011 (data as of 31 Dec 2011)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; PCR: Polymerase Chain Reaction; TS: Type Specific a Number of women tested b 95% Confidence Interval

Data Sources:

Data Sources: Systematic review and meta-analysis were performed by the ICO HPV Information Centre up to December 2011. Selected studies had to include at least 20 HIV positive women who had both normal cervical cytology and HPV test results (PCR or HC2).

4.1.4 Terminology

Cytologically normal women

No abnormal cells are observed on the surface of their cervix upon cytology.

Cervical Intraepithelial Neoplasia (CIN) / Squamous Intraepithelial Lesions (SIL)

SIL and CIN are two commonly used terms to describe precancerous lesions or the abnormal growth of squamous cells observed in the cervix. SIL is an abnormal result derived from cervical cytological screening or Pap smear testing. CIN is a histological diagnosis made upon analysis of cervical tissue obtained by biopsy or surgical excision. The condition is graded as CIN 1, 2 or 3, according to the thickness of the abnormal epithelium (1/3, 2/3 or the entire thickness).

Low-grade cervical lesions (LSIL/CIN-1)

Low-grade cervical lesions are defined by early changes in size, shape, and number of abnormal cells formed on the surface of the cervix and may be referred to as mild dysplasia, LSIL, or CIN-1.

High-grade cervical lesions (HSIL/ CIN-2 / CIN-3 / CIS)

High-grade cervical lesions are defined by a large number of precancerous cells on the surface of the cervix that are distinctly different from normal cells. They have the potential to become cancerous cells and invade deeper tissues of the cervix. These lesions may be referred to as moderate or severe dysplasia, HSIL, CIN-2, CIN-3 or cervical carcinoma in situ (CIS).

Carcinoma in situ (CIS)

Preinvasive malignancy limited to the epithelium without invasion of the basement membrane. CIN 3 encompasses the squamous carcinoma in situ.

Invasive cervical cancer (ICC) / Cervical cancer

If the high-grade precancerous cells invade the basement membrane is called ICC. ICC stages range from stage I (cancer is in the cervix or uterus only) to stage IV (the cancer has spread to distant organs, such as the liver).

Invasive squamous cell carcinoma

Invasive carcinoma composed of cells resembling those of squamous epithelium.

Adenocarcinoma

Invasive tumour with glandular and squamous elements intermingled.

Methods: Prevalence and type distribution of human papillomavirus in carcinoma of the vulva, vagina, anus and penis: systematic review and meta-analysis

A systematic review of the literature was conducted on the worldwide HPV-prevalence and type distribution for anogenital carcinomas other than cervix from January 1986 to 'data as of' indicated in each section. The search terms for the review were 'HPV' AND (anus OR anal) OR (penile) OR vagin* OR vulv* using Pubmed. There were no limits in publication language. References cited in selected articles were also investigated. Inclusion criteria were: HPV DNA detection by means of PCR, a minimum of 10 cases by lesion and a detailed description of HPV DNA detection and genotyping techniques used. The number of cases tested and HPV positive cases were extracted for each study to estimate the prevalence of HPV DNA and the HPV type distribution. Binomial 95% confidence intervals were calculated for each HPV prevalence.

4.2.1 Anal cancer and precancerous anal lesions

Anal cancer is similar to cervical cancer with respect to overall HPV DNA positivity, with approximately 100% of anal squamous cell carcinoma cases associated with HPV infection worldwide (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). HPV16 is the most common type detected, representing 73% of all HPV-positive tumours. HPV18 is the second most common type detected and is found in approximately 5% of cases. HPV DNA is also detected in the majority of precancerous anal lesions (AIN) (91.5% in AIN1 and 93.9% in AIN2/3) (De Vuyst H et al. Int J Cancer 2009; 124: 1626-36). In this section, the burden of HPV among cases of anal cancers and precancerous anal lesions in Czechia are presented.

Table 25: Studies on HPV prevalence among anal cancer cases in Czechia (male and female)

	HPV Prevalence						
Study	HPV detection method and targeted HPV types	No. Tested	%	(95% CI) ^a	Prevalence of 5 most frequent HPVs, HPV type (%)		
Alemany 2015 ^b	PCR-SPF10, EIA, (HPV 6, 11, 16, 18, 26, 30, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 67, 68, 69, 70, 73, 74, 82, 83, 87, 89, 91)	169	87.6	(81.8-91.7)	HPV 16 (73.4), HPV 18 (3.6), HPV 6 (3.6), HPV 11 (3.0), HPV 33 (2.4)		
Tachezy 2011	PCR L1-Consensus primer, , Sequencing (HPV 6, 11, 16, 18, 20, 21, 22, 23, 26, 30, 31, 32, 33, 34, 35, 38, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 80, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91)	26	73.1	(53.9-86.3)	HPV 16 (73.1)		

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific; 95% Confidence Interval

^b Includes cases from Bosnia-Herzegovina, Czech Republic, France, Germany, Poland, Portugal, Slovenia, Spain and United Kingdom

Data Sources:

Alemany L. Int J Cancer 2015: 136: 98 | Tachezy R. PLoS ONE 2011: 6: e21913

Epidemiology Group. The ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Bouvard V, Lancet Oncol 2009;10:321 2) De Vuyst H, Int J Cancer 2009;124:1626 Based on systematic reviews (up to 2008) performed by ICO for the IARC Monograph on the Evaluation of Carcinogenic Risks to Humans volume 100B and IARC's Infections and Cancer

Table 26: Studies on HPV prevalence among cases of AIN2/3 in Czechia

HPV Prevalence					
Study ^b	HPV detection method and targeted HPV types	No. Tested	%	(95% CI) ^a	Prevalence of 5 most frequent HPVs, HPV type (%)
Alemany 2015	PCR-SPF10, EIA, (HPV 6, 11, 16, 18, 26, 30, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 67, 68, 69, 70, 73, 74, 82, 83, 87, 89, 91)	23	95.7	(79.0-99.2)	HPV 16 (65.2), HPV 18 (8.7), HPV 51 (8.7), HPV 6 (8.7), HPV 74 (8.7)

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;


All 2/3: Anal intraepithelial neoplasia of grade 2/3 ^a 95% Confidence Interval ^b Includes cases from Bosnia-Herzegovina, Czech Republic, France, Germany, Poland, Portugal, Slovenia, Spain and United Kingdom

Data Sources

Alemany L. Int J Cancer 2015: 136: 98

Based on systematic reviews (up to 2008) performed by ICO for the IARC Monograph on the Evaluation of Carcinogenic Risks to Humans volume 100B and IARC's Infections and Cancer Epidemiology Group. The ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Bouvard V, Lancet Oncol 2009;10:321 2) De Vuyst H, Int J Cancer 2009;124:1626

Figure 62: Comparison of the ten most frequent HPV types in anal cancer cases in Europe and the World




Data updated on 9 Feb 2017 (data as of 30 Jun 2014)

^a Includes cases from Bosnia-Herzegovina, Czech Republic, France, Germany, Poland, Portugal, Slovenia, Spain and United Kingdom

^b Includes cases from Europe (Bosnia-Herzegovina, Czech Republic, France, Germany, Poland, Portugal, Slovenia, Spain and United Kingdom); America (Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay and United States); Africa (Mali, Nigeria and Senegal); Asia (Bangladesh, India and South Korea) Data Sources:

Data from Alemany L, Int J Cancer 2015; 136: 98. This study has gathered the largest international series of anal cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.

Figure 63: Comparison of the ten most frequent HPV types in AIN 2/3 cases in Europe and the World



Data updated on 7 Feb 2017 (data as of 30 Jun 2014)

AIN 2/3: Anal intraepithelial neoplasia of grade 2/3

Includes cases from Bosnia-Herzegovina, Czech Republic, France, Germany, Poland, Portugal, Slovenia, Spain and United Kingdom

b Includes cases from Europe (Bosnia-Herzegovina, Czech Republic, France, Germany, Poland, Portugal, Slovenia, Spain and United Kingdom); America (Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay)

Data Sources: Data from Alemany L, Int J Cancer 2015; 136: 98. This study has gathered the largest international series of anal cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay

4.2.2 Vulvar cancer and precancerous vulvar lesions

HPV attribution for vulvar cancer is 48% among age 15-54 years, 28% among age 55-64 years, and 15% among age 65+ worldwide (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Vulvar cancer has two distinct histological patterns with two different risk factor profiles: (1) basaloid/warty types (2) keratinising types. Basaloid/warty lesions are more common in young women, are frequently found adjacent to VIN, are very often associated with HPV DNA detection (86%), and have a similar risk factor profile as cervical cancer. Keratinising vulvar carcinomas represent the majority of the vulvar lesions (>60%). These lesions develop from non HPV-related chronic vulvar dermatoses, especially lichen sclerosus and/or squamous hyperplasia, their immediate cancer precursor lesion is differentiated VIN, they occur more often in older women, and are rarely associated with HPV (6%) or with any of the other risk factors typical of cervical cancer. HPV prevalence is frequently detected among cases of high-grade VIN (VIN2/3) (85.3%). HPV 16 is the most common type detected followed by HPV 33 (De Vuyst H et al. Int J Cancer 2009; 124: 1626-36). In this section, the HPV burden among cases of vulvar cancer cases and precancerous vulvar lesions in Czechia are presented.

Table 27: Studies on HPV prevalence among vulvar cancer cases in Czechia

			HPV	Prevalence	
Study	HPV detection method and targeted HPV types	No. Tested	%	(95% CI) ^a	Prevalence of 5 most frequent HPVs, HPV type (%)
de Sanjosé 2013 ^b	PCR-SPF10, EIA, (HPV 6, 11, 16, 18, 26, 30, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 67, 68, 69, 70, 73, 74, 82, 83, 87, 89, 91)	903	19.3	(16.8-22.0)	HPV 16 (13.8), HPV 33 (1.2), HPV 18 (0.6), HPV 31 (0.6), HPV 44 (0.4)
Tachezy 2011	PCR L1-Consensus primer, , Sequencing (HPV 6, 11, 16, 18, 20, 21, 22, 23, 26, 30, 31, 32, 33, 34, 35, 38, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 80, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91)	46	41.3	(28.3-55.7)	HPV 16 (23.9), HPV 33 (8.7), HPV 42 (2.2), HPV 45 (2.2), HPV 6 (2.2)

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific; 95% Confidence Interval

^b Includes cases from Austria, Belarus, Bosnia-Herzegovina, Czech Republic, France, Germany, Greece, Italy, Poland, Portugal, Spain and United Kingdom

Data Sources: de Saniosé S. Eur J. Cancer 2013: 49: 3450 | Tachezy R. PLoS ONE 2011: 6: e21913

Based on systematic reviews (up to 2008) performed by ICO for the IARC Monograph on the Evaluation of Carcinogenic Risks to Humans volume 100B and IARC's Infections and Cancer Epidemiology Group. The ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Bouvard V, Lancet Oncol 2009;10:321 2) De Vuyst H, Int J Cancer 2009:124:1626

Table 20. Studies on mill v prevalence anong vinv 2/0 cases in Ozecina	Table 28: Studies on	HPV prevalence amo	ong VIN 2/3 cases in Czechia
--	----------------------	--------------------	------------------------------

HPV Prevalence					
Study	HPV detection method and targeted HPV types	No. Tested	%	(95% CI) ^a	Prevalence of 5 most frequent HPVs, HPV type (%)
de Sanjosé 2013 ^b	PCR-SPF10, EIA, (HPV 6, 11, 16, 18, 26, 30, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 67, 68, 69, 70, 73, 74, 82, 83, 87, 89, 91)	312	86.9	(82.7-90.2)	HPV 16 (69.6), HPV 33 (11.2), HPV 18 (2.2), HPV 6 (1.6), HPV 52 (1.3)
Tachezy 2011	PCR L1-Consensus primer, , Sequencing (HPV 6, 11, 16, 18, 20, 21, 22, 23, 26, 30, 31, 32, 33, 34, 35, 38, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 57, 58, 59, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 80, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91)	94	94.7	(88.1-97.7)	HPV 16 (71.3), HPV 33 (8.5), HPV 18 (5.3), HPV 6 (4.3), HPV 11 (2.1)

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RTPCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific; VIN 2/3: Vulvar intraepithelial neoplasia of grade 2/3

95% Confidence Interval


^b Includes cases from Austria, Belarus, Bosnia-Herzegovina, Czech Republic, France, Germany, Greece, Italy, Poland, Portugal, Spain and United Kingdom Data Sources

de Sanjosé S, Eur J Cancer 2013; 49: 3450 | Tachezy R, PLoS ONE 2011; 6: e21913

- 70 -

Based on systematic reviews (up to 2008) performed by ICO for the IARC Monograph on the Evaluation of Carcinogenic Risks to Humans volume 100B and IARC's Infections and Cancer Epidemiology Group. The ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Bouvard V, Lancet Oncol 2009;10:321 2) De Vuyst H, Int J Cancer 2009;124:1626

Figure 64: Comparison of the ten most frequent HPV types in cases of vulvar cancer in Europe and the World




Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

^a Includes cases from Austria, Belarus, Bosnia-Herzegovina, Czech Republic, France, Germany, Greece, Italy, Poland, Portugal, Spain and United Kingdom.
 ^b Includes cases from America (Argentina, Brazil, Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay, Uruguay, United States of America and Venezuela); Africa (Mali, Mozambique, Nigeria, and Senegal); Oceania (Australia and New Zealand); Europe (Austria, Belarus, Bosnia-Herzegovina, Czech Republic, France, Germany, Greece, Italy, Poland, Portugal, Jpain and United Kingdom); and in Asia (Bangladesh, India, Israel, South Korea, Kuwait, Lebanon, Philippines, Taiwan and Turkey)

gal, Spain and United Kingdom); and in Asia (Bangladesh, India, Israel, South Korea, Kuwait, Lebanon, Philippines, Taiwan and Turkey) <u>Data Sources</u>: Data from de Sanjosé S, Eur J Cancer 2013; 49: 3450. This study has gathered the largest international series of vulva cancer cases and precancerous lesions worldwide using a standard

Data from de Sanjosé S, Eur J Cancer 2013; 49: 3450. This study has gathered the largest international series of vulva cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.

Figure 65: Comparison of the ten most frequent HPV types in VIN 2/3 cases in Europe and the World



Data updated on 30 Jun 2014 (data as of 30 Jun 2014)

VIN 2/3: Vulvar intraepithelial neoplasia of grade 2/3

^a Includes cases from Austria, Belarus, Bosnia-Herzegovina, Czech Republic, France, Germany, Greece, Italy, Poland, Portugal, Spain and United Kingdom.

^b Includes cases from America (Argentina, Brazil, Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay, Uruguay and Venezuela); Oceania (Australia and New Zealand); Europe (Austria, Belarus, Bosnia-Herzegovina, Czech Republic, France, Germany, Greece, Italy, Poland, Portugal, Spain and United Kingdom); and in Asia (Bangladesh, India, Israel, South Korea, Kuwait, Lebanon, Philippines, Taiwan and Turkey) Data Sources:

Data from de Sanjosé S, Eur J Cancer 2013; 49: 3450. This study has gathered the largest international series of vulva cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.

Vaginal cancer and precancerous vaginal lesions 4.2.3

Vaginal and cervical cancers share similar risk factors and it is generally accepted that both carcinomas share the same aetiology of HPV infection although there is limited evidence available. Women with vaginal cancer are more likely to have a history of other ano-genital cancers, particularly of the cervix, and these two carcinomas are frequently diagnosed simultaneously. HPV DNA is detected among 78% of invasive vaginal carcinomas and 91% of high-grade vaginal neoplasias (VaIN2/3). HPV16 is the most common type in high-grade vaginal neoplasias and it is detected in at least 78% of HPV-positive carcinomas (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190; De Vuyst H et al. Int J Cancer 2009; 124:1626-36). In this section, the HPV burden among cases of vaginal cancer cases and precancerous vaginal lesions in Czechia are presented.

Table 29: Studies on HPV prevalence among vaginal cancer cases in Czechia

HPV Prevalence						
Study ^b	HPV detection method and targeted HPV types	No. Tested	%	(95% CI) ^a	Prevalence of 5 most frequent HPVs, HPV type (%)	
Alemany 2014	PCR-SPF10, EIA, (HPV 6, 11, 16, 18, 26, 30, 31, 33, 35, 39, 42, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 73, 82)	152	71.1	(63.4-77.7)	HPV 16 (47.4), HPV 18 (3.3), HPV 73 (3.3), HPV 33 (2.6), HPV 56 (2.6)	

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific; 95% Confidence Interval

^b Includes cases from Austria, Belarus, Czech Republic, France, Germany, Greece, Poland, Spain and United Kingdom

Data Sources: Alemany L, Eur J Cancer 2014; 50: 2846

Based on systematic reviews (up to 2008) performed by ICO for the IARC Monograph on the Evaluation of Carcinogenic Risks to Humans volume 100B and IARC's Infections and Cancer Epidemiology Group. The ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Bouvard V, Lancet Oncol 2009;10:321 2) De Vuyst H, Int J Cancer 2009:124:1626

Table 30: Studies on HPV prevalence among VaIN 2/3 cases in Czechia

HPV Prevalence						
Study	HPV detection method and targeted HPV types	No. Tested	%	(95% CI) ^a	Prevalence of 5 most frequent HPVs, HPV type (%)	
Alemany 2014	PCR-SPF10, EIA, (HPV 6, 11, 16, 18, 26, 30, 31, 33, 35, 39, 42, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 73, 82)	96	97.9	(92.7-99.4)	HPV 16 (65.6), HPV 33 (7.3), HPV 18 (5.2), HPV 52 (3.1), HPV 73 (3.1)	

Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific; VAIN 2/3: Vaginal intraepithelial neoplasia of grade 2/3


a 95% Confidence Interval

Data Sources

Alemany L. Eur J Cancer 2014: 50: 2846

Based on systematic reviews (up to 2008) performed by ICO for the IARC Monograph on the Evaluation of Carcinogenic Risks to Humans volume 100B and IARC's Infections and Cancer Epidemiology Group. The ICO HPV Information Centre has updated data until June 2015. Reference publications: 1) Bouvard V, Lancet Oncol 2009;10:321 2) De Vuyst H, Int J Cancer 2009;124:1626

Figure 66: Comparison of the ten most frequent HPV types in cases of vaginal cancer in Europe and the World




Data updated on 30 Jun 2015 (data as of 30 Jun 2015)

^a Includes cases from Austria, Belarus, Czech Republic, France, Germany, Greece, Poland, Spain and United Kingdom.

^b Includes cases from Europe (Austria, Belarus, Czech Republic, France, Germany, Greece, Poland, Spain and United Kingdom); America (Argentina, Brazil, Chile, Colombia, Ecuador, Guatemala, Mexico, Paraguay, Uruguay, United states of America and Venezuela); Africa (Mozambique, Nigeria); Asia (Bangladesh, India, Israel, South Korea, Kuwait, Philippines, Taiwan and Turkey); and Oceania (Australia)

Data Sources: Data from Alemany L, Eur J Cancer 2014; 50: 2846. This study has gathered the largest international series of vaginal cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.

Figure 67: Comparison of the ten most frequent HPV types in VaIN 2/3 cases in Europe and the World



Data updated on 30 Jun 2014 (data as of 30 Jun 2014)

VAIN 2/3: Vaginal intraepithelial neoplasia of grade 2/3

^a Includes cases from Austria, Belarus, Czech Republic, France, Germany, Greece, Poland, Spain and United Kingdom.

b Includes cases from Flaveria, Belarus, Status, Statu

Data from Alemany L, Eur J Cancer 2014; 50: 2846. This study has gathered the largest international series of vaginal cancer cases and precancerous lesions worldwide using a standard protocol with a highly sensitive HPV DNA detection assay.

4.2.4 Penile cancer and precancerous penile lesions

HPV DNA is detectable in approximately 51% of all penile cancers (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). Among HPV-related penile tumours, HPV16 is the most common type detected, followed by HPV18 and HPV types 6/11 (Miralles C et al. J Clin Pathol 2009;62:870-8). Over 95% of invasive penile cancers are SCC and the most common penile SCC histologic sub-types are keratinising (49%), mixed warty-basaloid (17%), verrucous (8%), warty (6%), and basaloid (4%). HPV is commonly detected in basaloid and warty tumours but is less common in keratinising and verrucous tumours. In this section, the HPV burden among cases of penile cancer cases and precancerous penile lesions in Czechia are presented.

Table 31: Studies on HPV prevalence among penile cancer cases in Czechia

HPV Prevalence					
Study	HPV detection method and targeted HPV types	No. Tested	%	(95% CI) ^a	Prevalence of 5 most frequent HPVs, HPV type (%)
No data available	-	-	-	-	

Data updated on 5 Mar 2015 (data as of 30 Jun 2014)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific; a 95% Confidence Interval

Data Sources

The ICO HPV Information Centre has updated data until June 2014. Reference publications (up to 2008): 1) Bouvard V, Lancet Oncol 2009;10:321 2) Miralles-Guri C,J Clin Pathol 2009;62:870

Table 32: Studies on HPV prevalence among PeIN 2/3 cases in Czechia

	HPV Prevalence						
Study	HPV detection method and targeted HPV types	No. Tested	%	(95% CI) ^a	Prevalence of 5 most frequent HPVs, HPV type (%)		
No data available	-	-	-	-			

Data updated on 10 Feb 2015 (data as of 30 Jun 2014)


PeIN 2/3: Penile intraepithelial neoplasia of grade 2/3

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;

a 95% Confidence Interval

Data Sources: The ICO HPV Information Centre has updated data until June 2014. Reference publication (up to 2008): Bouvard V, Lancet Oncol 2009;10:321

Figure 68: Comparison of the ten most frequent HPV types in cases of penile cancer in Europe and the World



Data updated on 9 Feb 2017 (data as of 30 Jun 2015)


^a Includes cases from Czech Republic, France, Greece, Poland, Portugal, Spain and United Kingdom

^b Includes cases from Australia, Bangladesh, India, South Korea, Lebanon, Philippines, Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay, Venezuela and United States, Mozambique, Nigeria, Senegal, Czech Republic, France, Greece, Poland, Portugal, Spain and United Kingdo

Data Sources

Alemany L, Eur Urol 2016; 69: 953

Figure 69: Comparison of the ten most frequent HPV types in PeIN 2/3 cases in Europe and the World



Data updated on 9 Feb 2017 (data as of 30 Jun 2015)

PeIN 2/3: Penile intraepithelial neoplasia of grade 2/3

Includes cases from Czech Republic, France, Greece, Poland, Portugal, Spain and United Kingdom

^b Includes cases from Australia, Bangladesh, India, South Korea, Lebanon, Philippines, Chile, Colombia, Ecuador, Guatemala, Honduras, Mexico, Paraguay, Venezuela, Mozambique, Nigeria, Senegal, Czech Republic, France, Greece, Poland, Portugal, Spain and United Kingdom. Data Sources:

Ribeiro KB. Int J Epidemiol 2011: 40: 489

Based on systematic reviews and meta-analysis performed by ICO. Reference publications: 1) Ndiaye C, Lancet Oncol 2014; 15: 1319 2) Kreimer AR, Cancer Epidemiol Biomarkers Prev 2005: 14: 467

4.3 HPV burden in men

The information to date regarding anogenital HPV infection is primarily derived from cross-sectional studies of selected populations such as general population, university students, military recruits, and studies that examined husbands of control women, as well as from prospective studies. Special subgroups include mainly studies that examined STD (sexually transmitted diseases) clinic attendees, MSM (men who have sex with men), HIV positive men, and partners of women with HPV lesions, CIN (cervical intraepithelial neoplasia), cervical cancer or cervical carcinoma in situ. Globally, prevalence of external genital HPV infection in men is higher than cervical HPV infection in women, but persistence is less likely. As with genital HPV prevalence, high numbers of sexual partners increase the acquisition of oncogenic HPV infections (Vaccine 2012, Vol. 30, Suppl 5). In this section, the HPV burden among men in Czechia is presented.

Methods

HPV burden in men was based on published systematic reviews and meta-analyses (Dunne EF, J Infect Dis 2006; 194: 1044, Smith JS, J Adolesc Health 2011; 48: 540, Olesen TB, Sex Transm Infect 2014; 90: 455, and Hebnes JB, J Sex Med 2014; 11: 2630) up to October 31, 2015. The search terms for the review were human papillomavirus, men, polymerase chain reaction (PCR), hybrid capture (HC), and viral DNA. References cited in selected articles were also investigated. Inclusion criteria were: HPV DNA detection by means of PCR or HC (ISH if data are not available for the country), and a detailed description of HPV DNA detection and genotyping techniques used. The number of cases tested and HPV positive cases were extracted for each study to estimate the anogenital prevalence of HPV DNA. Binomial 95% confidence intervals were calculated for each anogenital HPV prevalence.

Table 55. Studies on The v prevalence among men in excerna										
					HPV	Prevalence				
Study	Anatomic sites samples	HPV detection method	Population	Age (years)	No. Tested	%	(95% CI) ^a			
-	-	-	-	-	-	-	-			

Table 33: Studies on HPV prevalence among men in Czechia

Data updated on 31 Oct 2015 (data as of 31 Oct 2015)

HC2: Hybrid Capture 2; ISH: In Situ Hybridization; PCR: Polymerase Chain Reaction; RT-PCR: Real Time Polymerase Chain Reaction; SPF: Short Primer Fragment; TS: Type Specific; MSM: Men who have sex with men; MSW:Men who have sex with women; STD: sexually transmitted diseases ^a 95% Confidence Interval

Data Sources:

Based on published systematic reviews, the ICO HPV Information Centre has updated data until October 2015. Reference publications: 1) Dunne EF, J Infect Dis 2006; 194: 1044 2) Smith JS, J Adolesc Health 2011; 48: 540 3) Olesen TB, Sex Transm Infect 2014; 90: 455 4) Hebnes JB, J Sex Med 2014; 11: 2630.

Table 34: Studies on HPV prevalence among men from special subgroups in Czechia

					HPV	Prevalence	
Study	Anatomic sites samples	HPV detection method	Population	Age (years)	No. Tested	%	(95% CI) ^a
-	-	-	-	-	-	-	

Data updated on 31 Oct 2015 (data as of 31 Oct 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLH: Reverse Line Hybridisation; RT-PCR: Real Time Polymerase Chain Reaction; SPF: Short Primer Fragment; TS: Type Specific; MSM: Men who have sex with men; MSW:Men who have sex with women; STD: sexually transmitted diseases ^a 95% Confidence Interval

Data Sources:

Based on published systematic reviews, the ICO HPV Information Centre has updated data until October 2015. Reference publications: 1) Dunne EF, J Infect Dis 2006; 194: 1044 2) Smith JS, J Adolesc Health 2011; 48: 540 3) Olesen TB, Sex Transm Infect 2014; 90: 455 4) Hebnes JB, J Sex Med 2014; 11: 2630.

4.4 HPV burden in the head and neck

The last evaluation of the International Agency for Research in Cancer (IARC) on the carcinogenicity of HPV in humans concluded that (a) there is enough evidence for the carcinogenicity of HPV type 16 in the oral cavity, oropharynx (including tonsil cancer, base of tongue cancer and other oropharyngeal cancer sites), and (b) limited evidence for laryngeal cancer (IARC Monograph Vol 100B). There is increasing evidence that HPV-related oropharyngeal cancers constitute an epidemiological, molecular and clinical distinct form as compared to non HPV-related ones. Some studies indicate that the most likely explanation for the origin of this distinct form of head and neck cancers associated with HPV is a sexually acquired oral HPV infection that is not cleared, persists and evolves into a neoplastic lesion. Around 30% of oropharyngeal cancers (which mainly comprises the tonsils and base of tongue sites) are caused by HPV with HPV16 being the most frequent type (de Martel C et al. Int J Cancer 2017;141(4):664-670). Attributable fraction varies greatly worldwide, being highest in more developed countries (60% in Republic of Korea, 51% in North America, 50% in Eastern Europe, 46% in Japan, 42% in North-Western Europe, 41% in Australia/New Zealand, 24% in South Europe, 23% in China, 22% in India, and 13% in elsewhere) (de Martel C et al. Lancet Glob Health 2020;8(2):e180-e190). In this section, the HPV burden in the head and neck in Czechia is presented.

4.4.1 Burden of oral HPV infection in healthy population

Study	Specimen collection method /	HPV detec- tion	Population	0%	Age (vears) ^b	No. tested ^c	HPV prevalence %	High-Risk HPV prevalence %	5 most frequent HPVs,
	anatomic site	method ^a		maies	$(years)^{o}$	tested	(95% CI)	(95% CI)	$\begin{array}{c} \mathbf{HPV} \\ \mathbf{type} \ (\mathbf{n})^d \end{array}$
-	_	-	-	-	_	_	_	_	_

Table 35: Studies on oral HPV prevalence among healthy in Czechia

Data updated on 19 Oct 2021 (data as of 19 May 2015)

(95% CI): 95% Confidence Interval

^a TS: type-specific; RT-PCR: real-time PCR; qPCR: quantitative PCR

^b NS: not specified

 c number of cases tested for HPV DNA d number of cases positive for the specific HPV-type

Data Sources:

Systematic review and meta-analysis was performed by ICO HPV Information Centre until May 19, 2015. Reference publication: Mena M et al. J Infect Dis 2019;219(10):1574-1585.

4.4.2 HPV burden in head and neck cancers

			HPV	Prevalence	
Study ^b	HPV detection method and targeted HPV types	No. Tested	%	(95% CI) ^a	Prevalence of 5 most frequent HPVs, HPV type (%)
MEN					
No data available	-	-	-	-	-
WOMEN					
No data available	-	-	-	-	-
BOTH OR UNSPECIE	'IED				
Ribeiro 2011	PGMY09/11 (L1) Amplification with TS primers (16)	132	0	-	-

Table 36: Studies on HPV prevalence among cases of oral cavity cancer in Czechia

Data updated on 9 May 2016 (data as of 31 Dec 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific;

Only for European countries

^a 95% Confidence Interval
^b Includes cases from Argentina, Brazil, Cuba, Russia, Slovakia, Czech Republic, Romania and Poland

Data Sources: Ribeiro KB, Int J Epidemiol 2011; 40: 489

Based on systematic reviews and meta-analysis performed by ICO. Reference publications: 1) Ndiaye C, Lancet Oncol 2014; 15: 1319 2) Kreimer AR, Cancer Epidemiol Biomarkers Prev 2005; 14: 467

Table 37: Studies on HPV prevalence among cases of oropharyngeal cancer in Czechia

	•	0	-	Prevalence	
Study	HPV detection method and targeted HPV types	No. Tested	%	(95% CI) ^a	Prevalence of 5 most frequent HPVs, HPV type (%)
MEN					
Rotnáglová 2011	GP5+/GP6+ (L1) RBLH (6. 11. 16. 18. 26. 31. 33. 34. 35. 39. 40. 42. 43. 44. 45. 51. 52. 53. 54. 55. 56. 57. 58. 59. 61. 66. 68. 70. 71. 72. 73. 81. 82. 83. 84. 89)	90	64.4	(54.2-73.6)	-
WOMEN					
Rotnáglová 2011	GP5+/GP6+ (L1) RBLH (6. 11. 16. 18. 26. 31. 33. 34. 35. 39. 40. 42. 43. 44. 45. 51. 52. 53. 54. 55. 56. 57. 58. 59. 61. 66. 68. 70. 71. 72. 73. 81. 82. 83. 84. 89)	19	68.4	(46.0-84.6)	-
BOTH OR UNSPECIFIE	D				
Klozar 2008	GP5+/GP6+ (L1) RLBH (6. 11. 16. 18. 26. 31. 33. 34. 35. 39. 40. 42. 43. 44. 45. 51. 52. 53. 54. 55. 56. 57. 58. 59. 61. 66. 68. 70. 71. 72. 73. 81. 82. 83. 84. 89)	20	45.0	(25.8-65.8)	HPV 16 (40.0) HPV 33 (5.0)
Ribeiro 2011	PGMY09/11 (L1) Amplification with TS primers (16)	136	0.7	(0.1-4.0)	HPV 16 (0.7)
Rotnáglová 2011	GP5+/GP6+ (L1) RBLH (6. 11. 16. 18. 26. 31. 33. 34. 35. 39. 40. 42. 43. 44. 45. 51. 52. 53. 54. 55. 56. 57. 58. 59. 61. 66. 68. 70. 71. 72. 73. 81. 82. 83. 84. 89)	109	65.1	(55.8-73.4)	HPV 16 (60.6) HPV 33 (1.8) HPV 18 (0.9) HPV 26 (0.9) HPV 52 (0.9)

Data updated on 9 May 2016 (data as of 31 Dec 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific

Only for European countries a 95% Confidence Interval

Data Sources:

Klozar J, Eur Arch Otorhinolaryngol 2008; 265 Suppl 1: S75 | Ribeiro KB, Int J Epidemiol 2011; 40: 489 | Rotnáglová E, Int J Cancer 2011; 129: 101

Based on systematic reviews and meta-analysis performed by ICO. Reference publications: 1) Ndiaye C, Lancet Oncol 2014; 15: 1319 2) Kreimer AR, Cancer Epidemiol Biomarkers Prev 2005; 14: 467

Table 38: Studies on HPV prevalence among cases of hypopharyngeal or laryngeal cancer in Czechia

HPV Prevalence								
Study ^b	HPV detection method and targeted HPV types	No. Tested	%	(95% CI) ^a	Prevalence of 5 most frequent HPVs, HPV type (%)			
MEN								
No data available	-	-	-	-	-			

Continued on next page

	Table 38 – continued from previous page										
Study ^b	HPV detection method and targeted HPV types	No. Tested	%	(95% CI) ^a	Prevalence of 5 most frequent HPVs, HPV type (%)						
WOMEN											
No data available	-	-	-	-	-						
BOTH OR UNSPECIF	IED										
Ribeiro 2011	PGMY09/11 (L1) Amplification with TS primers (16)	239	0.8	(0.2-3.0)	HPV 16 (0.8)						
Data undated on 9 May	2016 (data as of 31 Dec 2015)										

Data updated on 9 May 2016 (data as of 31 Dec 2015)

DBH: Dot Blot Hybridization; EIA: Enzyme ImmunoAssay; HC2: Hybrid Capture 2; ISH: In Situ Hybridization; LBA: Line-Blot Assay; LiPA: Line Probe Assay; PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; RLBH: Reverse Line Blot Hybridization; RT-PCR: Real Time Polymerase Chain Reaction; SBH: Southern Blot Hybridization; SPF: Short Primer Fragment; TS: Type Specific Only for European countries ^a 95% Confidence Interval ^b Includes cases from Argentina, Brazil, Cuba, Russia, Slovakia, Czech Republic, Romania and Poland Data Sources:

Data Sources: Ribeiro KB, Int J Epidemiol 2011; 40: 489 Based on systematic reviews and meta-analysis performed by ICO. Reference publications: 1) Ndiaye C, Lancet Oncol 2014; 15: 1319 2) Kreimer AR, Cancer Epidemiol Biomarkers Prev 2005; 14: 467

5 **Factors contributing to cervical cancer**

HPV is a necessary cause of cervical cancer, but it is not a sufficient cause. Other cofactors are necessary for progression from cervical HPV infection to cancer. Tobacco smoking, high parity, long-term hormonal contraceptive use, and co-infection with HIV have been identified as established cofactors. Co-infection with Chlamydia trachomatis and herpes simplex virus type-2, immunosuppression, and certain dietary deficiencies are other probable cofactors. Genetic and immunological host factors and viral factors other than type, such as variants of type, viral load and viral integration, are likely to be important but have not been clearly identified. (Muñoz N, Vaccine 2006; 24(S3): 1-10). In this section, the prevalence of smoking, parity (fertility), oral contraceptive use, and HIV in Czechia are presented.

INDICATOR		MALE	FEMALE	TOTAL
Smoking				
Smoking of any tobacco adjusted	Current ^a	36.6 [27.8-44.5]	27 [20.5-33]	31.7 [24.1-38.6]
prevalence (%) [95% UI]	Daily ^b	28.6 [22-35.6]	19.1 [14.9-23.8]	23.7 [18.3-29.6]
Cigarette smoking adjusted	Current ^c	36.6 [27.8-44.5]	27 [20.5-33]	31.7 [24.1-38.6]
prevalence (%) [95% UI]	Daily ^d	28.6 [22-35.6]	19.1 [14.9-23.8]	23.7 [18.3-29.6]
Parity				
Total fertility rate per woman		-	1.6	-
	15-19 yrs	-	11.8	-
	20-24 yrs	-	50.8	-
Age-specific fertility rate	25-29 yrs	-	103.7	-
(per 1000 women)	30-34 yrs	-	111.9	-
(per 1000 women)	35-39 yrs	-	49.8	-
	40-44 yrs	-	9.1	-
	45-49 yrs	-	0.5	-
Hormonal contraception Oral contraceptive use (%) among w married or in union		-	54.4	-
Injectable contraception use (%) a who are married or in union	among women	-	-	-
Implant contraceptive use (%) amor are married or in union	ng women who	-	-	-
HIV			·	
Estimated percent of adults aged living with HIV [95% UI]	15-49 who are	0.1 [0.1-0.1]	<0.1 [<0.1 -<0.1]	<0.1 [<0.1-<0.1]
Estimated percent of young adults a are living with HIV [95% UI]	-	<0.1 [<0.1 - <0.1]	<0.1 [<0.1-<0.1]	- [—]
HIV prevalence (%) among sex work	kers	1.6	0	0
HIV prevalence (%) among men who men	have sex with	4.8000002	-	4.8000002
Estimated number of people living v UI]	with HIV [95%	-	-	4400 [3700-5000]
Estimated number of adults (15+ y. HIV [95% UI]	rs) living with	3900 [3200-4500]	<500 [<500-<1000]	4400 [3700-5000]
Estimated number of AIDS-related	d deaths [95%	-	-	<100 [<100-<100]

Table 39: Factors contributing to cervical carcinogenesis (cofactors) in Czechia

Crude adjusted prevalence (%) estimates of tabacco use among people aged >= 15 years by country, for the year 2016.

a "Current" means smoking at the time of the survey, including both daily and non-daily or occasional smoking. "Tobacco smoking" means smoking any form of tobacco, including cigarettes, cigars, pipes, or any other smoked tobacco products and excluding smokeless products. ^b "Daily" means smoking every day at the time of the survey. "Tobacco smoking" means smoking any form of tobacco, including cigarettes, cigars, pipes, or any other smoked tobacco products

and excluding smokeless products. c "Current" means smoking at the time of the survey, including both daily and non-daily or occasional smoking.

 $d\,$ "Daily" means smoking every day at the time of the survey.

Data pertain to sexually active women of reproductive age. Data pertain to women with a partner Year of estimate: 2016

Data Sources

WHO global report on trends in prevalence of tobacco use 2000-2025, third edition. Geneva: World Health Organization; 2019. Available at https://www.who.int/publications/i/ item/who-global-report-on-trends-in-prevalence-of-2000-2025-third-editic bacco-use-Eurostat - Statistical office of the European Commission [web site]. Luxembourg: European Commission; 2017. Available at: https://ec.europa.eu/eurostat/web/products-datasets/ /demofrate. [Accessed on November 13, 2019].

des a/population/publications/dataset/contraception/wcu2019.asp. Available at: [Accessed on November 18, 2019]. UNAIDS database [internet]. Available at: http://aidsinfo.unaids.org/ [Accessed on November 21, 2019]

¹ The Bliss without Risk (NGO)

United Nations, Department of Economic and Social Affairs, Population Division (2017). World Population Prospects: The 2017 Revision, DVD Edition. Available at: https://www.un.org/ en/development/desa/population/publications/dataset/fertility/wfd2017.asp. [Accessed on November 13, 2019]. United Nations, Department of Economic and Social Affairs, Population Division (2019). World Contraceptive Use 2019 (POP/DB/CP/Rev2019). https://www.un.org/en/development/

Sexual and reproductive health behaviour indicators 6

Sexual intercourse is the primary route of transmission of genital HPV infection. Information about sexual and reproductive health behaviours is essential to the design of effective preventive strategies against anogenital cancers. In this section, we describe sexual and reproductive health indicators that may be used as proxy measures of risk for HPV infection and anogenital cancers. Several studies have reported that earlier sexual debut is a risk factor for HPV infection, although the reason for this relationship is still unclear. In this section, information on sexual and reproductive health behaviour in Czechia are presented.

Table 40: Percentage of 15-year-olds who have had sexual intercourse in Czechia

Indicator	Male	Female
Percentage of 15-year-old subjects who report sexual intercourse	23.0	24.0
Data accessed on 16 Mar 2017		

Please refer to original source for methods of estimation

Fifteen-year-olds teenagers only were asked whether they had ever had sexual intercourse.

Year of estimation: 2013-2014

Data Sources: Growing up unequal: gender and socioeconomic differences in young people's health and well-being. Health Behaviour in School-aged Children (HBSC) study: international report from the 2013/2014 survey. Inchley J, Currie D, Young T, et al. Copenhagen, WHO Regional Office for Europe, 2016 (Health Policy for Children and Adolescents, No. 7). Available at: http://www.euro.who.int/__data/assets/pdf_file/0003/303438/HSBC-No.7-Growing-up-unequal-Full-Report.pdf?ua=1

	Table 41: Median age at first sex in Czechia										
		MALE			FEMALE	TOTAL					
Study	Year/period	Birth cohort N	Ν	Median age at first sex	N	Median age at first sex	N	Median age at first sex			
Crochard 2009 ¹	2006-2007	1982-1988	530	17.0	509	17.0	-	-			
Czech Republic RHS 1993 ²	1993	1969-1978	-	-	1058	17.5	-	-			
Fronteira 2009 ^{3,a,b,c}	2005-2006	1986-1989	-	-	-	-	392	16.4			

Data accessed on 16 Mar 2017

Please refer to original source for methods of estimation a Data pertain to high school students.

 b Mean age at first sex.

^c Number of subjects refers to the number of surveyed men/women (not all sexually active).

Data Sources

1 Crochard A, Luyts D, di Nicola S, Gonçalves MAG. Self-reported sexual debut and behavior in young adults aged 18-24 years in seven European countries: implications for HPV vaccination Programs, Gynecol. Oncol. 2009 Dic;115(3 Suppl):S7-S14.
² Czech Statistical Office, WHO Collaborating Center for Perinatal Medicine/Institute for the Care of Mother and Child, Centers for Disease Control and Prevention, USA. Czech Republic

Reproductive Health Survey 1993. Centers for Disease Control and Prevention, Atlanta, Georgia. March 1995

³ Fronteira I, Oliveira da Silva M, Unzeitig V, Karro H, Temmerman M. Sexual and reproductive health of adolescents in Belgium, the Czech Republic, Estonia and Portugal. Eur J Contracept Reprod Health Care. 2009 Jun;14(3):215-220.

71 1 1 41 1 1 1. 1 C 1. α

Indicator		Male	Female
Average age at first marriage ¹		33.7	31.3
Age-specific % of ever married ²	15-19 years	0.02	0.16
	20-24 years	2.1	5.79
	25-29 years	13.45	25.73
	30-34 years	34.2	51.07
	35-39 years	54.03	68.69
	40-44 years	69.96	81.77
	45-49 years	80.85	90.38
	50-54 years	86.55	93.96
	55-59 years	89.35	95.52
	60-64 years	92.01	96.48
	65-69 years	94.35	97.1
	70-74 years	96.19	97.42
	+75	97.55	97.84

Table 42: Marriage patterns in Czechia

Data accessed on 20 Feb 2020 Please refer to original source for methods of estimation.

^a 2018 Estimate ^b UNSD

Data Sources: The world bank: health nutrition and population statistics. Updated 20-Dec-2019. Accessed on February 20 2020. Available at http://data.worldbank.org/data-catalog/ health-nutrition-and-population-statistics ² United Nations, Department of Economic and Social Affairs, Population Division (2019). World Marriage Data 2019 (POP/DB/Marr/Rev2019). Available at: https://population.un.

org/MarriageData/Index.html#/home Accessed on February 24, 2020.

Table 43: Average number of sexual partners in Czechia

$\mathbf{Study}^{a,1}$	Period of estimate	Year/Period	Birth cohort	Male Mean(N)	Female Mean(N)	Total Mean(N)
Crochard 2009	Lifetime	2006-2007	(1982-1989)	4.0(518)	3.0(505)	-(-)

Data accessed on 8 Aug 2013 Please refer to original source for methods of estimation ^a Median number of sexual partners.

Data Sources:

1 Crochard A, Luyts D, di Nicola S, Gonçalves MAG. Self-reported sexual debut and behavior in young adults aged 18-24 years in seven European countries: implications for HPV vaccination programs. Gynecol. Oncol. 2009 Dic;115(3 Suppl):S7-S14.

Table 44: Lifetime	prevalence of anal intercourse among womer	ı in Czechia
Table II. Linetime	prevalence of anal meeteoarse among women	i ili Olooilla

			FEMALE		
\mathbf{Study}^{a}	Year/Period	Birth cohort	N surveyed	N sexual active	% among sexually active
Brody 2011	1993	<=1978	-	542	16.6
Brody 2011	1998	<=1983	-	696	18.0
Brody 2011	2003	<=1988	-	799	17.4
Brody 2011	2008	<=1993	-	843	19.7

Data accessed on 8 Aug 2013 Please refer to original source for methods of estimation ^a Instead of number of women sexually active, this time was number of women who answered the question on anal intercourse.

Data Sources: Brody S, Weiss P. Heterosexual anal intercourse: increasing prevalence, and association with sexual dysfunction, bisexual behavior, and venereal disease history. J Sex Marital Ther. 2011 Sep;37(4):298-306.

7 HPV preventive strategies

It is established that well-organised cervical screening programmes or widespread good quality cytology can reduce cervical cancer incidence and mortality. The introduction of HPV vaccination could also effectively reduce the burden of cervical cancer in the coming decades. This section presents indicators on basic characteristics and performance of cervical cancer screening, status of HPV vaccine licensure and introduction in Czechia.

7.1 Cervical cancer screening practices

Screening strategies differ between countries. Some countries have population-based programmes, where in each round of screening women in the target population are individually identified and invited to attend screening. This type of programme can be implemented nationwide or only in specific regions of the country. In opportunistic screening, invitations depend on the individual's decision or on encounters with health-care providers. The most frequent method for cervical cancer screening is cytology, and there are alternative methods such as HPV DNA tests and visual inspection with acetic acid (VIA). VIA is an alternative to cytology-based screening in low-resource settings (the 'see and treat' approach). HPV DNA testing is being introduced into some countries as an adjunct to cytology screening ('co-testing') or as the primary screening test to be followed by a secondary, more specific test, such as cytology.

Table 45: Main characteristics of cervical	cancer screening in Czechia
--	-----------------------------

Region	Existence of official national recommendations	Starting year of current recommendations	Active invitation to screening	Screening ages (years), primary screening test used, and screening interval or frequency of screenings
Czech Republic	Yes	2014	Yes	25-60 (cytology, 1 year)

Data accessed on 31 Aug 2022

Data Sources: Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. Lancet Glob Health. 2022;10(8):e1115.




Figure 70: Estimated coverage* of cervical cancer screening in Czechia

Data accessed on 31 Aug 2022 * Estimated coverage and 95% confidence interval in 2019 <u>Data Sources:</u> Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. Lancet Glob Health. 2022;10(8):e1115.

7.2 HPV vaccination

Table 46: National HPV Immunization programme in Czechia

	Female	Male
HPV vaccination programme	Introduced	Introduced
Year of introduction	2012	2018
Year of estimation of HPV vaccination coverage	2021	2021
HPV coverage – first dose (%)	-	-
HPV coverage – last dose (%)	-	-
		1

Data accessed on 24 Oct 2022

Data Sources: Human papillomavirus (HPV) vaccination coverage. World Health Organization. 2022. Available from: https://immunizationdata.who.int/pages/coverage/hpv.html, accessed [24 Oct 2022]

Oct 2022] Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med. 2021;144(106399):106399.

Figure 71: HPV vaccination coverage in females by year in Czechia

No data available

Data accessed on 24 Oct 2022

Data Sources: Human papillomavirus (HPV) vaccination coverage. World Health Organization. 2022. Available from: https://immunizationdata.who.int/pages/coverage/hpv.html, accessed [24 Oct 2022]

Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med. 2021;144(106399):106399.




Figure 72: HPV vaccination coverage in males by year in Czechia

Data accessed on 24 Oct 2022

Data accessed on D4 Oct 2022 Data Sources: Human papillomavirus (HPV) vaccination coverage. World Health Organization. 2022. Available from: https://immunizationdata.who.int/pages/coverage/hpv.html, accessed [24 Oct 2022] Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med. 2021;144(106399):106399.

Protective factors for cervical cancer 8

Male circumcision and the use of condoms have shown a significant protective effect against HPV transmission.

Table 47: Prevalence of male circumcision in Czechia				
Reference	Prevalence % (95% CI)	Methods		
WHO 2007	<20	Data from Demographic and Health Surveys (DHS) and other publications to categorize the country-wide prevalence of male circumcision as <20%, 20-80%, or >80%.		

Data accessed on 31 Aug 2015

Please refer to country-specific refere ence(s) for full methodologies.

Data Sources: WHO 2007: Male circumcision: Global trends and determinants of prevalence, safety and acceptability Based on systematic reviews and meta-analysis performed by ICO. The ICO HPV Information Centre has updated data until August 2015. Reference publication: Albero G, Sex Transm Dis. 2012 Feb;39(2):104-13.

Table 48: Prevalence of condom use in Czechia

Indicator	Age range	Year of estimate	Prevalence % ^a
Condom use	18-44	2008	13.1

Data accessed on 18 Nov 2019

Please refer to original source for methods of estimation. Data pertain to sexually active women of reproductive age. Data pertain to women with a partner.

^a Condom use: Proportion of male partners who are using condoms with their female partners of reproductive age to whom they are married or in union by country. Data Sources:

2008 GGS

United Nations, Department of Economic and Social Affairs, Population Division (2019). World Contraceptive Use 2019 (POP/DB/CP/Rev2019). https://www.un.org/en/development/ desa/population/publications/dataset/contraception/wcu2019.asp. Available at: [Accessed on November 18, 2019].

9 Annex

9.1 Incidence

9.1.1 Cervical cancer incidence in Czechia across Eastern Europe




Figure 73: Age-standardised incidence rates of cervical cancer of Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 women per year.






Figure 74: Annual number of new cases of cervical cancer by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 7 cases for Eastern Europe in the 15-19 age group.





Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

9.1.2 Anal cancer incidence in Czechia across Eastern Europe




Figure 76: Age-standardised incidence rates of anal cancer of Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.

^b Rates per 100,000 women per year.




Figure 77: Annual number of new cases of anal cancer among men by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
^a 0 cases for Czechia and 1 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 0 cases for Eastern Europe in the 20-24 age group. 0 cases for Czechia and 1 cases for




Figure 78: Annual number of new cases of anal cancer among women by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 0 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 2 cases for Eastern Europe in the 20-24 age group. 0 cases for Czechia and 2 cases for Eastern Europe in the 25-29 age group.




Figure 79: Comparison of age-specific anal cancer incidence rates among men by age in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year. <u>Data Sources:</u> Ferlay J. Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].




Figure 80: Comparison of age-specific anal cancer incidence rates among women by age in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

15-19.

20-24

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

30-34

25-29.

12

40-44

35-39 -

0

Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

50-54

55-59

60-64

62-69

70-74

75-79

80-84

Age group (years)

85+

45-49.

9.1.3 Vulva cancer incidence in Czechia across Eastern Europe






Figure 81: Age-standardised incidence rates of vulva cancer of Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

Data Sources:





Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 0 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 3 cases for Eastern Europe in the 20-24 age group. 1 cases for Czechia and 7 cases for Eastern Europe in the 25-29 age group. 2 cases for Czechia and 33 cases for Eastern Europe in the 30-34 age group.




Figure 83: Comparison of age-specific vulva cancer incidence rates in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

Data accessed on 2/Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 women per year. Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.1.4 Vaginal cancer incidence in Czechia across Eastern Europe




Figure 84: Age-standardised incidence rates of vaginal cancer of Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

Data Sources:






Figure 85: Annual number of new cases of cervical cancer by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 0 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 1 cases for Eastern Europe in the 20-24 age group. 0 cases for Czechia and 1 cases for Eastern Europe in the 25-29 age group. 0 cases for Czechia and 7 cases for Eastern Europe in the 30-34 age group.





Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year. <u>Data Sources</u>: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.1.5 Penile cancer incidence in Czechia across Eastern Europe




Figure 87: Age-standardised incidence rates of penile cancer of Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

Data Sources:

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.




Figure 88: Annual number of new cases of penile cancer by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 0 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 2 cases for Eastern Europe in the 20-24 age group. 0 cases for Czechia and 6 cases for Eastern Europe in the 25-29 age group. 1 cases for Czechia and 19 cases for Eastern Europe in the 30-34 age group.




Figure 89: Comparison of age-specific penile cancer incidence rates in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

Data accessed on 2/Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 men per year. Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.1.6 Oropharyngeal cancer incidence in Czechia across Eastern Europe




Figure 90: Age-standardised incidence rates of oropharyngeal cancer of Czechia (estimates for 2020)

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 men per year.

b Rates per 100,000 women per year.






Figure 91: Annual number of new cases of oropharyngeal cancer among men by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 1 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 1 cases for Eastern Europe in the 20-24 age group. 0 cases for Czechia and 9 cases for Eastern Europe in the 25-29 age group. 0 cases for Czechia and 31 cases for Eastern Europe in the 30-34 age group. 6 cases for Czechia and 41 cases for Eastern Europe in the 85+ age

Eastern Europe in the 20-20 age group. O cases for Ozecina and of cases for Datastin Datapenn in the of the generic structure of the second property of the seco





Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 2 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 0 cases for Eastern Europe in the 20-24 age group. 0 cases for Czechia and 3 cases for Eastern Europe in the 25-29 age group. 0 cases for Czechia and 19 cases for Eastern Europe in the 30-34 age group.




Figure 93: Comparison of age-specific oropharyngeal cancer incidence rates among men by age in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 men per year.





Figure 94: Comparison of age-specific oropharyngeal cancer incidence rates among women by age in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

Figure 95: Age-standardised incidence rates of oral cavity cancer of Czechia (estimates for 2020) Males Females

9.1.7 Oral cavity cancer incidence in Czechia across Eastern Europe



Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.

b Rates per 100,000 women per year.




Figure 96: Annual number of new cases of oral cavity cancer among men by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 1 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 11 cases for Eastern Europe in the 20-24 age group. 1 cases for Czechia and 34 cases for Eastern Europe in the 25-29 age group. 2 cases for Czechia and 97 cases for Eastern Europe in the 30-34 age group.




Figure 97: Annual number of new cases of oral cavity cancer among women by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 2 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 7 cases for Eastern Europe in the 20-24 age group. 1 cases for Czechia and 13 cases for Eastern Europe in the 25-29 age group. 3 cases for Czechia and 46 cases for Eastern Europe in the 30-34 age group.




Figure 98: Comparison of age-specific oral cavity cancer incidence rates among men by age in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.




Figure 99: Comparison of age-specific oral cavity cancer incidence rates among women by age in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 women per year.

Figure 100: Age-standardised incidence rates of laryngeal cancer of Czechia (estimates for 2020) Males Females Hungary 8.23 1.78 Poland 8.39 1.11 Republic of Moldova 11.9 0.72 Romania 11.4 0.61

4.27

9.1.8 Laryngeal cancer incidence in Czechia across Eastern Europe

6.0 0 6.0 Laryngeal cancer: Age-standardised incidence laryngeal per 100,000 men and women World Standard. Male and Female (All ages)

0.61

0.60

0.43

0.38

0.30

0.19

Data accessed on 27 Jan 2021

Bulgaria

Czechia

Slovakia

Ukraine

Belarus

Russian Federation

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.

9.22

7.67

7.74

6.61

8.69

^b Rates per 100,000 women per year.





Figure 101: Annual number of new cases of laryngeal cancer among men by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 0 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 1 cases for Eastern Europe in the 20-24 age group. 0 cases for Czechia and 5 cases for Eastern Europe in the 25-29 age group. 0 cases for Czechia and 23 cases for Eastern Europe in the 30-34 age group. 1 cases for Czechia and 98 cases for Eastern Europe in the 35-39 age

Eastern Europe in the 20-20 age group, o cases for Ozechia and 20 cases for Eastern Europe in the contract of the contract of



84

45-49.

48

40-44

24

35-39

Figure 102: Annual number of new cases of laryngeal cancer among women by age group in Czechia (estimates for 2020)

15-19.

20-24

25-29.

100

0

17

30-34

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 0 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 4 cases for Eastern Europe in the 20-24 age group. 0 cases for Czechia and 6 cases for Eastern Europe in the 25-29 age group. Deto Source:

50-54

55-59.

60-64

65-69

70-74

75-79.

Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

80

80-84

Age group (years)

63

85+




Figure 103: Comparison of age-specific laryngeal cancer incidence rates among men by age in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.




Figure 104: Comparison of age-specific laryngeal cancer incidence rates among women by age in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

9.2 Mortality

9.2.1 Cervical cancer mortality in Czechia across Eastern Europe




Figure 105: Age-standardised mortality rates of cervical cancer of Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

Data Sources:




Figure 106: Annual number of deaths of cervical cancer by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 0 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 11 cases for Eastern Europe in the 20-24 age group.




Figure 107: Comparison of age-specific cervical cancer mortality rates in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

9.2.2 Anal cancer mortality in Czechia across Eastern Europe




Figure 108: Age-standardised mortality rates of anal cancer of Czechia (estimates for 2020)

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.

b Rates per 100,000 women per year.




Figure 109: Annual number of deaths of anal cancer among men by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods
^a 0 cases for Czechia and 0 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 1 cases for Eastern Europe in the 20-24 age group. 0 cases for Czechia and 3 cases for Eastern Europe in the 25-29 age group.




Figure 110: Annual number of deaths of anal cancer among women by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 0 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 0 cases for Eastern Europe in the 20-24 age group. 0 cases for Czechia and 0 cases for Eastern Europe in the 25-29 age group. 0 cases for Czechia and 0 cases for Eastern Europe in the 30-34 age group.




Figure 111: Comparison of age-specific anal cancer mortality rates among men by age in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year. <u>Data Sources:</u> Ferlay J. Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].




Figure 112: Comparison of age-specific anal cancer mortality rates among women by age in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

9.2.3 Vulva cancer mortality in Czechia across Eastern Europe




Figure 113: Age-standardised mortality rates of vulva cancer of Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

Data Sources:




Figure 114: Annual number of deaths of vulva cancer by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods @ 0 cases for Czechia and 1 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 0 cases for Eastern Europe in the 20-24 age group. 0 cases for Czechia and 4 cases for Eastern Europe in the 25-29 age group. 0 cases for Czechia and 13 cases for Eastern Europe in the 30-34 age group. 0 cases for Czechia and 20 cases for Eastern Europe in the 45-49 age group. Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].




Figure 115: Comparison of age-specific vulva cancer mortality rates in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

Data accessed on 2/Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 women per year. Data Sources: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

Vaginal cancer mortality in Czechia across Eastern Europe 9.2.4






Figure 116: Age-standardised mortality rates of vaginal cancer of Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

Data Sources:





Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 0 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 0 cases for Eastern Europe in the 25-29 age group. 0 cases for Czechia and 1 cases for Eastern Europe in the 25-29 age group. 0 cases for Czechia and 1 cases for Eastern Europe in the 30-34 age group. 0 cases for Czechia and 1 cases for Eastern Europe in the 35-39 age group.




Figure 118: Comparison of age-specific vaginal cancer mortality rates in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year. <u>Data Sources</u>: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.2.5 Penile cancer mortality in Czechia across Eastern Europe






Figure 119: Age-standardised mortality rates of penile cancer of Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.

Data Sources:





Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 0 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 2 cases for Eastern Europe in the 20-24 age group. 0 cases for Czechia and 0 cases for Eastern Europe in the 25-29 age group. 0 cases for Czechia and 2 cases for Eastern Europe in the 30-34 age group.




Figure 121: Comparison of age-specific penile cancer mortality rates in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year. <u>Data Sources:</u> Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].

9.2.6 **Oropharyngeal cancer mortality in Czechia across Eastern Europe**




Figure 122: Age-standardised mortality rates of oropharyngeal cancer of Czechia (estimates for 2020)

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.

b Rates per 100,000 women per year.





Figure 123: Annual number of deaths of oropharyngeal cancer among men by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a 0 cases for Czechia and 0 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 0 cases for Eastern Europe in the 25-29 age group. 0 cases for Czechia and 16 cases for Eastern Europe in the 30-34 age group. 2 cases for Czechia and 38 cases for Eastern Europe in the 35-39 age group. 3 cases for Czechia and 41 cases for Eastern Europe in the 85+ age group.



21

40-44

Figure 124: Annual number of deaths of oropharyngeal cancer among women by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

15-19.

20-24

25-29.

0

а

30-34

35-39

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 0 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 0 cases for Eastern Europe in the 25-29 age group. 0 cases for Czechia and 1 cases for Eastern Europe in the 30-34 age group. 0 cases for Czechia and 4 cases for Eastern Europe in the 35-39 age group.

50-54

55-59.

60-64

65-69

70-74

75-79.

80-84

Age group (years)

85+

45-49.




Figure 125: Comparison of age-specific oropharyngeal cancer mortality rates among men by age in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.

Data Sources:




Figure 126: Comparison of age-specific oropharyngeal cancer mortality rates among women by age in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

9.2.7 Oral cavity cancer mortality in Czechia across Eastern Europe




Figure 127: Age-standardised mortality rates of oral cavity cancer of Czechia (estimates for 2020)

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.

b Rates per 100,000 women per year.




Figure 128: Annual number of deaths of oral cavity cancer among men by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 2 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 0 cases for Eastern Europe in the 20-24 age group. 0 cases for Czechia and 10 cases for Eastern Europe in the 25-29 age group. 0 cases for Czechia and 23 cases for Eastern Europe in the 30-34 age group.




Figure 129: Annual number of deaths of oral cavity cancer among women by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 1 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 2 cases for Eastern Europe in the 20-24 age group. 0 cases for Czechia and 7 cases for Eastern Europe in the 25-29 age group. 0 cases for Czechia and 9 cases for Eastern Europe in the 30-34 age group.




Figure 130: Comparison of age-specific oral cavity cancer mortality rates among men by age in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 men per year. <u>Data Sources</u>: Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [27 January 2021].




Figure 131: Comparison of age-specific oral cavity cancer mortality rates among women by age in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 women per year.

9.2.8 Laryngeal cancer mortality in Czechia across Eastern Europe




Figure 132: Age-standardised mortality rates of laryngeal cancer of Czechia (estimates for 2020)

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods a Rates per 100,000 men per year.

b Rates per 100,000 women per year.




Figure 133: Annual number of deaths of laryngeal cancer among men by age group in Czechia (estimates for 2020)

15-19

20-24

25-29

30-34

35-39

40-44

Data accessed on 27 Jan 2021 For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 0 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 0 cases for Eastern Europe in the 20-24 age group. 0 cases for Czechia and 1 cases for Eastern Europe in the 25-29 age group. 0 cases for Czechia and 15 cases for Eastern Europe in the 30-34 age group. 0 cases for Czechia and 45 cases for Eastern Europe in the 35-39 age

45-49

50-54

55-59

60-64

62-69

70-74

75-79

80-84

Age group (years)

85+




Figure 134: Annual number of deaths of laryngeal cancer among women by age group in Czechia (estimates for 2020)

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a 0 cases for Czechia and 0 cases for Eastern Europe in the 15-19 age group. 0 cases for Czechia and 1 cases for Eastern Europe in the 20-24 age group. 0 cases for Czechia and 2 cases for Eastern Europe in the 25-29 age group. 0 cases for Czechia and 3 cases for Eastern Europe in the 30-34 age group.




Figure 135: Comparison of age-specific laryngeal cancer mortality rates among men by age in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 men per year.




Figure 136: Comparison of age-specific laryngeal cancer mortality rates among women by age in Czechia, within the region, and the rest of world

Data accessed on 27 Jan 2021

For more detailed methods of estimation please refer to http://gco.iarc.fr/today/data-sources-methods ^a Rates per 100,000 women per year.

10 Glossary

Table 49: Glossary Term Definition Incidence is the number of new cases arising in a given period in a specified population. This information is collected routinely by cancer registries. Incidence It can be expressed as an absolute number of cases per year or as a rate per 100,000 persons per year (see Crude rate and ASR below). The rate provides an approximation of the average risk of developing a cancer. Mortality is the number of deaths occurring in a given period in a specified Mortality population. It can be expressed as an absolute number of deaths per year or as a rate per 100,000 persons per year. The prevalence of a particular cancer can be defined as the number of persons in a defined population who have been diagnosed with that type of cancer, and who are still alive at the end of a given year, the survivors. Complete prevalence represents the number of persons alive at certain point in time who previously had a diagnosis of the disease, regardless of how long ago the diagnosis was, or if the patient is still under treatment or is considered cured. Partial prevalence, which limits the number of patients to those diagnosed during a fixed time in the past, is a particularly useful Prevalence measure of cancer burden. Prevalence of cancers based on cases diagnosed within one, three and five are presented as they are likely to be of relevance to the different stages of cancer therapy, namely, initial treatment (one year), clinical follow-up (three years) and cure (five years). Patients who are still alive five years after diagnosis are usually considered cured since the death rates of such patients are similar to those in the general population. There are exceptions, particularly breast cancer. Prevalence is presented for the adult population only (ages 15 and over), and is available both as numbers and as proportions per 100,000 persons. Data on incidence or mortality are often presented as rates. For a specific tumour and population, a crude rate is calculated simply by dividing the number of new cancers or cancer deaths observed during a given time pe-Crude rate riod by the corresponding number of person years in the population at risk. For cancer, the result is usually expressed as an annual rate per 100,000 persons at risk. An age-standardised rate (ASR) is a summary measure of the rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age because age has a powerful influence on the risk of cancer. The ASR is a weighted mean of the age-specific rates; the weights are taken from population distribution of the standard population. The most frequently ASR (age-standardised used standard population is the World Standard Population. The calcurate) lated incidence or mortality rate is then called age-standardised incidence or mortality rate (world). It is also expressed per 100,000. The world standard population used in GLOBOCAN is as proposed by Segi [1] and modified by Doll and al. [2]. The age-standardised rate is calculated using 10 age-groups. The result may be slightly different from that computed using the same data categorised using the traditional 5 year age bands.

Continued on next page

Table 49 – continued from previous page	
Term	Definition
Cumulative risk	Cumulative incidence/mortality is the probability or risk of individuals get- ting/dying from the disease during a specified period. For cancer, it is ex- pressed as the number of new born children (out of 100, or 1000) who would be expected to develop/die from a particular cancer before the age of 75 if they had the rates of cancer observed in the period in the absence of com- peting causes.
Cytologically normal women	No abnormal cells are observed on the surface of their cervix upon cytology.
Cervical Intraepithe- lial Neoplasia (CIN) / Squamous Intraepithe- lial Lesions (SIL)	SIL and CIN are two commonly used terms to describe precancerous lesions or the abnormal growth of squamous cells observed in the cervix. SIL is an abnormal result derived from cervical cytological screening or Pap smear testing. CIN is a histological diagnosis made upon analysis of cervical tis- sue obtained by biopsy or surgical excision. The condition is graded as CIN 1, 2 or 3, according to the thickness of the abnormal epithelium (1/3, 2/3 or the entire thickness).
Low-grade cervical le- sions (LSIL/CIN-1)	Low-grade cervical lesions are defined by early changes in size, shape, and number of ab-normal cells formed on the surface of the cervix and may be referred to as mild dysplasia, LSIL, or CIN-1.
High-grade cervical le- sions (HSIL / CIN-2 / CIN-3 / CIS)	High-grade cervical lesions are defined by a large number of precancerous cells on the sur-face of the cervix that are distinctly different from normal cells. They have the potential to become cancerous cells and invade deeper tissues of the cervix. These lesions may be referred to as moderate or severe dysplasia, HSIL, CIN-2, CIN-3 or cervical carcinoma in situ (CIS).
Carcinoma in situ (CIS)	Preinvasive malignancy limited to the epithelium without invasion of the basement membrane. CIN 3 encompasses the squamous carcinoma in situ.
Invasive cervical can- cer (ICC) / Cervical	If the high-grade precancerous cells invade the basement membrane is called ICC. ICC stages range from stage I (cancer is in the cervix or uterus
cancer Adenocarcinoma	only) to stage IV (the cancer has spread to distant organs, such as the liver). Invasive tumour with glandular and squamous elements intermingled

Acknowledgments

This report has been developed by the Unit of Infections and Cancer, Cancer Epidemiology Research Program, at the Institut Català d'Oncologia (ICO, Catalan Institute of Oncology). This report was supported by a grant from the Instituto de Salud Carlos III (Spanish Government) through the projects PI18/01137, PI21/00982, PI22/00219 and CIBERESP CB06/02/0073, and the Secretariat for Universities and Research of the Department of Business and knowledge of the Government of Catalonia grants to support the activities of research groups (SGR 2017–2021) (Grant number 2017SRG1718 and 2021SGR01029). The report has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 847845. We thank the CERCA Program / Generalitat de Catalunya for institutional support. The HPV Information Centre is being developed by the ICO. The Centre was originally launched by ICO with the collaboration of WHO's Immunisation, Vaccines and Biologicals (IVB) department and support from the Bill and Melinda Gates Foundation.

Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), in alphabetic order

Albero G, Amarilla S, Bosch FX, Bruni L, Collado JJ, de Sanjosé S, Gómez D, Mena M, Muñoz J, Ruiz FJ, Serrano B.

International Agency for Research on Cancer (IARC)

Note to the reader

Anyone who is aware of relevant published data that may not have been included in the present report is encouraged to contact the HPV Information Centre for potential contributions.

Although efforts have been made by the HPV Information Centre to prepare and include as accurately as possible the data presented, mistakes may occur. Readers are requested to communicate any errors to the HPV Information Centre, so that corrections can be made in future volumes.

Disclaimer

The information in this database is provided as a service to our users. Any digital or printed publication of the information provided in the web site should be accompanied by an acknowledgment of HPV Information Centre as the source. Systematic retrieval of data to create, directly or indirectly, a scientific publication, collection, database, directory or website requires a permission from HPV Information Centre.

The responsibility for the interpretation and use of the material contained in the HPV Information Centre lies on the user. In no event shall the HPV Information Centre be liable for any damages arising from the use of the information.

Licensed Logo Use

Use, reproduction, copying, or redistribution of HPV Information Centre logo is strictly prohibited without written explicit permission from the HPV Information Centre.

Contact information:

ICO/IARC HPV Information Centre Institut Català d'Oncologia Avda. Gran Via de l'Hospitalet, 199-203 08908 L'Hospitalet de Llobregat (Barcelona, Spain) e-mail: info@hpvcentre.net internet address: www.hpvcentre.net

